1
|
Varzaru B, Iacob RA, Bunduc S, Manea I, Sorop A, Spiridon A, Chelaru R, Croitoru A, Topala M, Becheanu G, Dumbrava M, Dima S, Popescu I, Gheorghe C. Prognostic Value of Circulating Cell-Free DNA Concentration and Neutrophil-to-Lymphocyte Ratio in Patients with Pancreatic Ductal Adenocarcinoma: A Prospective Cohort Study. Int J Mol Sci 2024; 25:2854. [PMID: 38474101 DOI: 10.3390/ijms25052854] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2023] [Revised: 02/25/2024] [Accepted: 02/26/2024] [Indexed: 03/14/2024] Open
Abstract
Circulating cell-free DNA (ccfDNA) quantity correlates with the clinical characteristics and prognosis of various cancer types. We investigated whether ccfDNA levels and the neutrophil-to-lymphocyte ratio (NLR) have prognostic value in patients with pancreatic ductal adenocarcinoma (PDAC). Peripheral blood was collected from 82 patients with PDAC prior to any diagnostic procedure or the administration of chemotherapy. Plasma DNA was isolated, and ccfDNA concentration and NLR were determined. We found that ccfDNA levels were correlated with age and tumor burden. Moreover, higher values of NLR (≥3.31) were linked with worse overall survival (OS) (4 vs. 10 months; log rank p = 0.011), and an elevated ccfDNA concentration (≥25.79 ng/mL) was strongly associated with shorter OS (4 vs. 8 months; log rank p = 0.009). According to the results of the multivariable Cox regression analysis, the baseline concentration of ccfDNA was an independent prognostic factor for OS (HR 0.45, 95% CI 0.21-0.97, p = 0.041). Furthermore, the combination of ccfDNA levels with NLR greatly enhanced the prognostic accuracy of PDAC patients. Our study demonstrates that ccfDNA concentration and NLR are independent predictors of survival in PDAC. Subsequent studies should validate this combination as a prognostic indicator in PDAC patients and assess its utility for guiding therapeutic decisions.
Collapse
Affiliation(s)
- Bianca Varzaru
- Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania
- Center of Excellence in Translational Medicine, Fundeni Clinical Institute, 022328 Bucharest, Romania
| | - Razvan Andrei Iacob
- Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania
- Center of Excellence in Translational Medicine, Fundeni Clinical Institute, 022328 Bucharest, Romania
- Digestive Diseases and Liver Transplantation Center, Fundeni Clinical Institute, 022238 Bucharest, Romania
| | - Stefania Bunduc
- Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania
- Center of Excellence in Translational Medicine, Fundeni Clinical Institute, 022328 Bucharest, Romania
- Digestive Diseases and Liver Transplantation Center, Fundeni Clinical Institute, 022238 Bucharest, Romania
| | - Ioana Manea
- Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania
- Center of Excellence in Translational Medicine, Fundeni Clinical Institute, 022328 Bucharest, Romania
| | - Andrei Sorop
- Center of Excellence in Translational Medicine, Fundeni Clinical Institute, 022328 Bucharest, Romania
| | - Andreea Spiridon
- Center of Excellence in Translational Medicine, Fundeni Clinical Institute, 022328 Bucharest, Romania
| | - Raluca Chelaru
- Center of Excellence in Translational Medicine, Fundeni Clinical Institute, 022328 Bucharest, Romania
| | - Adina Croitoru
- Center of Excellence in Translational Medicine, Fundeni Clinical Institute, 022328 Bucharest, Romania
- Digestive Diseases and Liver Transplantation Center, Fundeni Clinical Institute, 022238 Bucharest, Romania
| | - Mihaela Topala
- Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania
- Center of Excellence in Translational Medicine, Fundeni Clinical Institute, 022328 Bucharest, Romania
| | - Gabriel Becheanu
- Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania
- Center of Excellence in Translational Medicine, Fundeni Clinical Institute, 022328 Bucharest, Romania
- Digestive Diseases and Liver Transplantation Center, Fundeni Clinical Institute, 022238 Bucharest, Romania
| | - Mona Dumbrava
- Center of Excellence in Translational Medicine, Fundeni Clinical Institute, 022328 Bucharest, Romania
- Digestive Diseases and Liver Transplantation Center, Fundeni Clinical Institute, 022238 Bucharest, Romania
| | - Simona Dima
- Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania
- Center of Excellence in Translational Medicine, Fundeni Clinical Institute, 022328 Bucharest, Romania
- Digestive Diseases and Liver Transplantation Center, Fundeni Clinical Institute, 022238 Bucharest, Romania
| | - Irinel Popescu
- Center of Excellence in Translational Medicine, Fundeni Clinical Institute, 022328 Bucharest, Romania
- Digestive Diseases and Liver Transplantation Center, Fundeni Clinical Institute, 022238 Bucharest, Romania
| | - Cristian Gheorghe
- Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania
- Center of Excellence in Translational Medicine, Fundeni Clinical Institute, 022328 Bucharest, Romania
- Digestive Diseases and Liver Transplantation Center, Fundeni Clinical Institute, 022238 Bucharest, Romania
| |
Collapse
|
2
|
Kraft A, Moldovan C, Bârcu A, Dumitru R, Croitoru A, Herlea V, Popescu I, Botea F. Salvage Hepatectomy for Giant GIST Liver Metastases Unresponsive to Systemic Therapy-Case Report. Life (Basel) 2023; 13:1681. [PMID: 37629538 PMCID: PMC10456077 DOI: 10.3390/life13081681] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2023] [Revised: 07/21/2023] [Accepted: 08/01/2023] [Indexed: 08/27/2023] Open
Abstract
Therapeutic decision-making for advanced GIST liver metastases is challenging due to limited clinical evidence. This case study aims to demonstrate the survival benefit of resection in non-responsive cases. A 40-year-old male presented with abdominal pain, weight loss, altered general status, massive hepatomegaly, and intermittent melaena. He was diagnosed with stage IV GIST with the primary tumor in the ileal loop and multiple gigantic synchronous bilobar liver metastases. Despite 31 months of tyrosine-kinase inhibitor therapy post-primary tumor resection, the disease remained unresponsive. The patient was admitted to our tertiary center with significant hepatomegaly. A two-stage debulking liver resection was performed after a multidisciplinary team decision. The first operation debulked the left hemiliver through a non-anatomical ultrasound-guided resection of segments 2, 3, and 4. The second operation (7 weeks later) debulked the right hemiliver through a right posterior sectionectomy involving segments 5 and 8. Despite receiving a second line of tyrosine-kinase inhibitor therapy after surgery, the disease progressed both within and outside the liver. However, the patient survived for 55 months, with a postoperative survival benefit of 25 months. In conclusion, this case emphasizes the significant survival benefit achieved through a complex two-stage debulking liver resection for giant liver metastases, even in cases where systemic therapy fails.
Collapse
Affiliation(s)
- Alin Kraft
- Department of General Surgery, “Regina Maria” Military Emergency Hospital, 500007 Brașov, Romania;
| | - Cosmin Moldovan
- Department of General Surgery, Witting Clinical Hospital, 010243 Bucharest, Romania
- Department of Medical-Clinical Disciplines, Faculty of Medicine, “Titu Maiorescu” University of Bucharest, 031593 Bucharest, Romania; (A.C.); (V.H.); (I.P.); (F.B.)
| | - Alexandru Bârcu
- Doctoral School in Medicine, “Titu Maiorescu” University, 040441 Bucharest, Romania;
| | - Radu Dumitru
- Department of Radiology and Medical Imaging, “Fundeni” Clinical Institute, 050474 Bucharest, Romania;
| | - Adina Croitoru
- Department of Medical-Clinical Disciplines, Faculty of Medicine, “Titu Maiorescu” University of Bucharest, 031593 Bucharest, Romania; (A.C.); (V.H.); (I.P.); (F.B.)
- Department of Oncology, “Fundeni” Clinical Institute, 022328 Bucharest, Romania
| | - Vlad Herlea
- Department of Medical-Clinical Disciplines, Faculty of Medicine, “Titu Maiorescu” University of Bucharest, 031593 Bucharest, Romania; (A.C.); (V.H.); (I.P.); (F.B.)
- Department of Pathology, “Fundeni” Clinical Institute, 022328 Bucharest, Romania
| | - Irinel Popescu
- Department of Medical-Clinical Disciplines, Faculty of Medicine, “Titu Maiorescu” University of Bucharest, 031593 Bucharest, Romania; (A.C.); (V.H.); (I.P.); (F.B.)
- “Dan Setlacec” Center for General Surgery and Liver Transplant, “Fundeni” Clinical Institute, 022328 Bucharest, Romania
| | - Florin Botea
- Department of Medical-Clinical Disciplines, Faculty of Medicine, “Titu Maiorescu” University of Bucharest, 031593 Bucharest, Romania; (A.C.); (V.H.); (I.P.); (F.B.)
- “Dan Setlacec” Center for General Surgery and Liver Transplant, “Fundeni” Clinical Institute, 022328 Bucharest, Romania
| |
Collapse
|
3
|
Kraft A, Bârcu A, Barzan D, Dumitru R, Croitoru A, Herlea V, Popescu I, Botea F. The Survival Benefit of Repetitive Ultrasound-Guided Liver Resections in the Absence of Chemotherapy for Multiple Colorectal Recurrent Liver Metastases. Chirurgia (Bucur) 2023; 118:229-236. [PMID: 37480349 DOI: 10.21614/chirurgia.2023.v.118.i.3.p.229] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/01/2023] [Indexed: 07/24/2023]
Abstract
We present the case of a 54-year-old female patient, diagnosed with stage IV rectal cancer, with multiple (12) synchronous liver metastases, the largest of 10 cm in diameter, bilobar distributed. The operative management consisted in simultaneous ultra-low robotic anterior resection with coloanal anastomosis (protected by ileostomy) and multiple ultrasound-guided non-anatomical liver resections (in open approach). The patient was unable to follow neoadjuvant and adjuvant chemotherapy due to the systemic side effects. The intrahepatic disease presented 2 episodes of recurrence, sanctioned by ultrasound-guided non-anatomical parenchyma sparing liver resections. In total 32 liver metastases were addressed (31 resected and 1 radiofrequency ablated). The patient presented 1 episode of lung recurrence, sanctioned by right superior lobectomy and lymphadenectomy for a singular metastasis. The patient died with disease progression both intra-, and extrahepatically after 34 months post first surgical intervention.
Collapse
|
4
|
Stroie T, Preda C, Istratescu D, Ciora C, Croitoru A, Diculescu M. Anxiety and depression in patients with inactive inflammatory bowel disease: The role of fatigue and health-related quality of life. Medicine (Baltimore) 2023; 102:e33713. [PMID: 37171347 PMCID: PMC10174368 DOI: 10.1097/md.0000000000033713] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 05/13/2023] Open
Abstract
Inflammatory bowel diseases (IBD) are chronic conditions characterized by a remitting-relapsing course. Patients with IBD have an impaired quality of life and are more often affected by anxiety and depression. This study aimed to evaluate the prevalence and severity of anxiety and depression in patients with inactive IBD, and to identify factors associated with them. A total of 132 consecutive patients diagnosed with IBD for over 3 months that were in corticosteroid-free remission at the time of assessment were enrolled in this observational, cross-sectional study. Anxiety, depression, fatigue, and health-related quality of life (HR-QoL) were evaluated using the following self-administered questionnaires: HADS, Functional Assessment of Chronic Illness Therapy-Fatigue, and IBDQ 32. Symptoms of anxiety and depression were considered for HADS-A > 7 points and HADS-D > 7 points, respectively. Out of the 132 patients included, 76 (57.6%) were men. The median patient age was 38 years (interquartile range 30-47). Eighty-three patients (62.9%) were diagnosed with Crohn disease, and 49 (37.1%) with ulcerative colitis. Most of the patients were treated with biologics (85.6%). Anxiety was identified in 34.1% of patients, and two thirds of them (68.9%) had mild symptoms. A lower proportion of patients were presenting symptoms of depression (18.2%), the vast majority (91.7%) having mild forms. In the multivariate analysis, anxiety was significantly associated with fatigue [odds ratio (OR) 4.39, 95% confidence interval (CI): 1.22-15.79, P = .02] and lower HR-QoL (OR 2.46, 95% CI: 1.70-3.91, P < .001), while depression was associated with exposure to multiple biologics (OR 3.33, 95% CI: 1.01-10.97, P = .04) and fatigue (OR 9.70, 95% CI: 1.67-56.27, P = .01). In conclusion, anxiety and depression are highly prevalent in patients with IBD even during the periods of remission. Both anxiety and depression are associated with fatigue. In addition, lower HR-QoL is associated with anxiety and exposure to multiple biologics with depression.
Collapse
Affiliation(s)
- Tudor Stroie
- "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania
- Gastroenterology Department, Fundeni Clinical Institute, Bucharest, Romania
| | - Carmen Preda
- "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania
- Gastroenterology Department, Fundeni Clinical Institute, Bucharest, Romania
| | - Doina Istratescu
- "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania
- Gastroenterology Department, Fundeni Clinical Institute, Bucharest, Romania
| | - Cosmin Ciora
- "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania
- Gastroenterology Department, Fundeni Clinical Institute, Bucharest, Romania
| | - Adina Croitoru
- "Titu Maiorescu" University, Bucharest, Romania
- Oncology Department, Fundeni Clinical Institute, Bucharest, Romania
| | - Mircea Diculescu
- "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania
- Gastroenterology Department, Fundeni Clinical Institute, Bucharest, Romania
| |
Collapse
|
5
|
Stroie T, Preda C, Meianu C, Istrătescu D, Manuc M, Croitoru A, Gheorghe L, Gheorghe C, Diculescu M. Fatigue Is Associated with Anxiety and Lower Health-Related Quality of Life in Patients with Inflammatory Bowel Disease in Remission. Medicina (B Aires) 2023; 59:medicina59030532. [PMID: 36984533 PMCID: PMC10058711 DOI: 10.3390/medicina59030532] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2023] [Revised: 03/04/2023] [Accepted: 03/07/2023] [Indexed: 03/11/2023] Open
Abstract
Background and Objectives: Inflammatory bowel diseases (IBD) are chronic conditions with an unpredictable course and a remitting–relapsing evolution. Fatigue is a frequent complaint in patients with IBD, affecting approximately half of the newly diagnosed patients with IBD. The aim of this study was to analyze fatigue in patients with IBD in remission. Materials and Methods: One hundred nineteen consecutive outpatients diagnosed with IBD for over 3 months that were in corticosteroid-free clinical and biochemical remission at the time of assessment were included in this cross-sectional study. Out of them, 72 (60.5%) were male; the median age was 39 years (IQR 30–47). Seventy-seven patients (64.7%) were diagnosed with Crohn’s disease and forty-two (35.3%) with ulcerative colitis, with a median disease duration of 6 years (IQR 2–10). Fatigue, health-related quality of life (HR-QoL), anxiety and depression were evaluated using the following self-administered questionnaires: FACIT Fatigue, IBDQ 32 and HADS. Results: The mean FACIT-Fatigue score was 41.6 (SD ± 8.62), and 38.7% of patients were revealed as experiencing fatigue when a cut-off value of 40 points was used. The mean IBDQ 32 score was 189.4 (SD ± 24.1). Symptoms of anxiety and depression were detected in 37% and 21% of the patients, respectively. In the multivariate analysis, fatigue was significantly associated with lower HR-QoL (OR 2.21, 95% CI: 1.42–3.44, p < 0.001), symptoms of anxiety (OR 5.04, 95% CI: 1.20–21.22, p = 0.008), female sex (OR 3.32, 95% CI: 1.02–10.76, p = 0.04) and longer disease duration (OR 1.13, 95% CI: 1.01–1.27, p = 0.04). Conclusions: Fatigue is highly prevalent even in patients with inactive IBD and is correlated with lower HR-QoL and anxiety, as well as with clinical factors such as longer disease duration and female sex.
Collapse
Affiliation(s)
- Tudor Stroie
- Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania
- Gastroenterology Department, Fundeni Clinical Institute, 022328 Bucharest, Romania
- Correspondence:
| | - Carmen Preda
- Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania
- Gastroenterology Department, Fundeni Clinical Institute, 022328 Bucharest, Romania
| | - Corina Meianu
- Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania
- Gastroenterology Department, Fundeni Clinical Institute, 022328 Bucharest, Romania
| | - Doina Istrătescu
- Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania
- Gastroenterology Department, Fundeni Clinical Institute, 022328 Bucharest, Romania
| | - Mircea Manuc
- Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania
- Gastroenterology Department, Fundeni Clinical Institute, 022328 Bucharest, Romania
| | - Adina Croitoru
- Faculty of Medicine, Titu Maiorescu University, 040441 Bucharest, Romania
- Oncology Department, Fundeni Clinical Institute, 022328 Bucharest, Romania
| | - Liana Gheorghe
- Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania
- Gastroenterology Department, Fundeni Clinical Institute, 022328 Bucharest, Romania
| | - Cristian Gheorghe
- Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania
- Gastroenterology Department, Fundeni Clinical Institute, 022328 Bucharest, Romania
| | - Mircea Diculescu
- Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania
- Gastroenterology Department, Fundeni Clinical Institute, 022328 Bucharest, Romania
| |
Collapse
|
6
|
Dumitru A, Dobrica EC, Croitoru A, Cretoiu SM, Gaspar BS. Focus on PD-1/PD-L1 as a Therapeutic Target in Ovarian Cancer. Int J Mol Sci 2022; 23:ijms232012067. [PMID: 36292922 PMCID: PMC9603705 DOI: 10.3390/ijms232012067] [Citation(s) in RCA: 11] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2022] [Revised: 09/27/2022] [Accepted: 10/06/2022] [Indexed: 12/24/2022] Open
Abstract
Ovarian cancer is considered one of the most aggressive and deadliest gynecological malignancies worldwide. Unfortunately, the therapeutic methods that are considered the gold standard at this moment are associated with frequent recurrences. Survival in ovarian cancer is associated with the presence of a high number of intra tumor infiltrating lymphocytes (TILs). Therefore, immunomodulation is considered to have an important role in cancer treatment, and immune checkpoint inhibitors may be useful for restoring T cell-mediated antitumor immunity. However, the data presented in the literature until now are not sufficient to allow for the identification and selection of patients who really respond to immunotherapy among those with ovarian cancer. Although there are some studies with favorable results, more prospective trials are needed in this sense. This review focuses on the current and future perspectives of PD-1/L1 blockade in ovarian cancer and analyzes the most important immune checkpoint inhibitors used, with the aim of achieving optimal clinical outcomes. Future studies and trials are needed to maximize the efficacy of immune checkpoint blockade therapy in ovarian cancer, as well as in all cancers, in general.
Collapse
Affiliation(s)
- Adrian Dumitru
- Department of Pathology, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania
- Department of Pathology, University Emergency Hospital of Bucharest, 050098 Bucharest, Romania
| | - Elena-Codruta Dobrica
- Department of Pathophysiology, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania
- Department of Dermatology, Elias University Hospital, 011461 Bucharest, Romania
| | - Adina Croitoru
- Department of Medical Oncology, Fundeni Clinical Institute, 022328 Bucharest, Romania
- Department of Oncology, Titu Maiorescu University, 031593 Bucharest, Romania
| | - Sanda Maria Cretoiu
- Department of Cell and Molecular Biology and Histology, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania
- Correspondence:
| | - Bogdan Severus Gaspar
- Surgery Department, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania
- Surgery Clinic, Bucharest Emergency Clinical Hospital, 014461 Bucharest, Romania
| |
Collapse
|
7
|
Cerban R, Croitoru A, Becheanu G, Iacob S, Ester C, Ghioca M, Grasu M, Dumitru R, Preda C, Florescu M, Gheorghe L. Cholangiocellular carcinoma occurrence after HCV eradication therapy: case series and review of the literature. J Med Life 2022; 15:1257-1266. [DOI: 10.25122/jml-2022-0102] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2022] [Accepted: 09/16/2022] [Indexed: 11/21/2022] Open
Abstract
Hepatitis C viral (HCV) treatment has rapidly advanced with the use of direct-acting antivirals (DAA), and many patients achieve sustained virological response (SVR). Although the risk of liver tumors is greatly reduced, there are still patients who achieve SVR but will progress to hepatocellular carcinoma (HCC). HCV infection is also a known risk for cholangiocellular carcinoma (CLC), although it is considered a relative infrequent liver malignancy. We report a series of five cases of CLC in patients that achieved SVR after HCV treatment with DAA. There were three women and two males with a median age of 62 years (range 49 to 77 years). Four patients had liver cirrhosis at the time of their HCV treatment. The interval from achieving SVR until CLC diagnosis varied, ranging from 4 to 36 months (median=12). Three patients presented with advanced disease and had extrahepatic spread at the time of their diagnosis. One patient had a resectable tumor, with no recurrence 4 years later. In one case, the tumor was initially considered an atypical HCC and was treated by radiofrequency ablation. Three years later, she was diagnosed with a large tumor recurrence that was demonstrated to be a CLC on liver biopsy. The last two patients were older males with HCV compensated cirrhosis diagnosed with CLC more than two years after achieving SVR. Palliative chemotherapy was started in both. Only a handful of CLC cases have been reported in HCV patients after SVR. Clinicians should take into account the possible development of an aggressive CLC.
Collapse
|
8
|
Wysocki O, Zhou C, Rogado J, Huddar P, Shotton R, Tivey A, Albiges L, Angelakas A, Arnold D, Aung T, Banfill K, Baxter M, Barlesi F, Bayle A, Besse B, Bhogal T, Boyce H, Britton F, Calles A, Castelo-Branco L, Copson E, Croitoru A, Dani SS, Dickens E, Eastlake L, Fitzpatrick P, Foulon S, Frederiksen H, Ganatra S, Gennatas S, Glenthøj A, Gomes F, Graham DM, Hague C, Harrington K, Harrison M, Horsley L, Hoskins R, Hudson Z, Jakobsen LH, Joharatnam-Hogan N, Khan S, Khan UT, Khan K, Lewis A, Massard C, Maynard A, McKenzie H, Michielin O, Mosenthal AC, Obispo B, Palmieri C, Patel R, Pentheroudakis G, Peters S, Rieger-Christ K, Robinson T, Romano E, Rowe M, Sekacheva M, Sheehan R, Stockdale A, Thomas A, Turtle L, Viñal D, Weaver J, Williams S, Wilson C, Dive C, Landers D, Cooksley T, Freitas A, Armstrong AC, Lee RJ. An International Comparison of Presentation, Outcomes and CORONET Predictive Score Performance in Patients with Cancer Presenting with COVID-19 across Different Pandemic Waves. Cancers (Basel) 2022; 14:3931. [PMID: 36010932 PMCID: PMC9406013 DOI: 10.3390/cancers14163931] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2022] [Revised: 08/04/2022] [Accepted: 08/08/2022] [Indexed: 12/15/2022] Open
Abstract
Patients with cancer have been shown to have increased risk of COVID-19 severity. We previously built and validated the COVID-19 Risk in Oncology Evaluation Tool (CORONET) to predict the likely severity of COVID-19 in patients with active cancer who present to hospital. We assessed the differences in presentation and outcomes of patients with cancer and COVID-19, depending on the wave of the pandemic. We examined differences in features at presentation and outcomes in patients worldwide, depending on the waves of the pandemic: wave 1 D614G (n = 1430), wave 2 Alpha (n = 475), and wave 4 Omicron variant (n = 63, UK and Spain only). The performance of CORONET was evaluated on 258, 48, and 54 patients for each wave, respectively. We found that mortality rates were reduced in subsequent waves. The majority of patients were vaccinated in wave 4, and 94% were treated with steroids if they required oxygen. The stages of cancer and the median ages of patients significantly differed, but features associated with worse COVID-19 outcomes remained predictive and did not differ between waves. The CORONET tool performed well in all waves, with scores in an area under the curve (AUC) of >0.72. We concluded that patients with cancer who present to hospital with COVID-19 have similar features of severity, which remain discriminatory despite differences in variants and vaccination status. Survival improved following the first wave of the pandemic, which may be associated with vaccination and the increased steroid use in those patients requiring oxygen. The CORONET model demonstrated good performance, independent of the SARS-CoV-2 variants.
Collapse
Affiliation(s)
- Oskar Wysocki
- Department of Computer Science, University of Manchester, Oxford Road, Manchester M13 9PL, UK; (O.W.); (A.F.)
- Digital Experimental Cancer Medicine Team, Cancer Biomarker Centre, Cancer Research UK Manchester Institute, University of Manchester, Alderley Park, Macclesfield SK10 4TG, UK; (P.F.)
| | - Cong Zhou
- Digital Experimental Cancer Medicine Team, Cancer Biomarker Centre, Cancer Research UK Manchester Institute, University of Manchester, Alderley Park, Macclesfield SK10 4TG, UK; (P.F.)
| | - Jacobo Rogado
- Cancer Research UK Manchester Institute, Cancer Biomarker Centre, The University of Manchester, Al-derley Park, Macclesfield SK10 4TG, UK; (C.Z.); (C.D.)
| | - Prerana Huddar
- Department of Medical Oncology, Hospital Universitario Infanta Leonor, Av. Gran Vía del Este, 80, 28031 Madrid, Spain; (J.R.); (B.O.)
| | - Rohan Shotton
- Department of Computer Science, University of Manchester, Oxford Road, Manchester M13 9PL, UK; (O.W.); (A.F.)
- Department of Medical Oncology, Hospital Universitario Infanta Leonor, Av. Gran Vía del Este, 80, 28031 Madrid, Spain; (J.R.); (B.O.)
| | - Ann Tivey
- Department of Computer Science, University of Manchester, Oxford Road, Manchester M13 9PL, UK; (O.W.); (A.F.)
- Department of Medical Oncology, Hospital Universitario Infanta Leonor, Av. Gran Vía del Este, 80, 28031 Madrid, Spain; (J.R.); (B.O.)
| | - Laurence Albiges
- Department of Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Road, Manchester M20 4BX, UK; (P.H.); (R.S.); (A.T.); (A.A.); (K.B.); (F.B.); (F.G.); (D.M.G.); (C.H.); (L.H.); (A.L.); (J.W.); (T.C.); (A.C.A.)
| | - Angelos Angelakas
- Department of Medical Oncology, Hospital Universitario Infanta Leonor, Av. Gran Vía del Este, 80, 28031 Madrid, Spain; (J.R.); (B.O.)
| | - Dirk Arnold
- Faculty of Biology, Medicine and Health, The University of Manchester, Oxford Road, Manchester M13 9PL, UK; (O.W.)
| | - Theingi Aung
- Department of Medical Oncology, Gustave Roussy, 94805 Villejuif, France; (L.A.); (F.B.)
| | - Kathryn Banfill
- Department of Computer Science, University of Manchester, Oxford Road, Manchester M13 9PL, UK; (O.W.); (A.F.)
- Department of Medical Oncology, Hospital Universitario Infanta Leonor, Av. Gran Vía del Este, 80, 28031 Madrid, Spain; (J.R.); (B.O.)
| | - Mark Baxter
- Department of Oncology, Haematology and Palliative Care, Asklepios Klinik Altona, Paul-Ehrlich-Str. 1, 22763 Hamburg, Germany;
| | - Fabrice Barlesi
- Department of Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Road, Manchester M20 4BX, UK; (P.H.); (R.S.); (A.T.); (A.A.); (K.B.); (F.B.); (F.G.); (D.M.G.); (C.H.); (L.H.); (A.L.); (J.W.); (T.C.); (A.C.A.)
- Weston Park Cancer Centre, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield S10 2JF, UK; (T.A.); (H.B.); (A.M.); (R.S.); (S.W.); (C.W.)
| | - Arnaud Bayle
- Division of Molecular and Clinical Medicine, Ninewells School of Medicine, University of Dundee, Dundee DD2 1SY, UK;
- Multidisciplinary Oncology & Therapeutic Innovations Department, Aix Marseille University, CNRS, INSERM, CRCM, 13015 Marseille, France
| | - Benjamin Besse
- Division of Molecular and Clinical Medicine, Ninewells School of Medicine, University of Dundee, Dundee DD2 1SY, UK;
| | - Talvinder Bhogal
- Drug Development Department (DITEP), Gustave Roussy—Cancer Campus, 94805 Villejuif, France; (A.B.); (B.B.); (C.M.)
| | - Hayley Boyce
- Department of Medical Oncology, Gustave Roussy, 94805 Villejuif, France; (L.A.); (F.B.)
| | - Fiona Britton
- Department of Medical Oncology, Hospital Universitario Infanta Leonor, Av. Gran Vía del Este, 80, 28031 Madrid, Spain; (J.R.); (B.O.)
| | - Antonio Calles
- Oncostat (CESP U1018 INSERM), Labeled Ligue Contre le Cancer, University Paris-Saclay, 94805 Villejuif, France;
| | - Luis Castelo-Branco
- Department of Medical Oncology, The Clatterbridge Cancer Centre NHS Foundation Trust, 65 Pembroke Place, Liverpool L7 8YA, UK; (T.B.); (U.T.K.); (C.P.)
- Department of Medical Oncology, Hospital General Universitario Gregorio Marañón, Calle del Dr. Esquerdo, 46, 28007 Madrid, Spain;
- ESMO-CoCARE Steering Committee, European Society for Medical Oncology, Via Ginevra 4, 6900 Lugano, Switzerland; (L.C.-B.); (G.P.); (S.P.)
| | - Ellen Copson
- NOVA National School of Public Health, Av. Padre Cruz, 1600-560 Lisboa, Portugal
| | - Adina Croitoru
- Department of Medical Oncology, University Hospital Center of Algarve, R. Leao Penedo, 8000-386 Faro, Portugal
| | - Sourbha S. Dani
- Cancer Sciences Academic Unit, University Hospital Southampton NHS Foundation Trust, Tremona Road, Southampton SO16 6YD, UK; (E.C.); (H.M.)
| | - Elena Dickens
- Medical Oncology Department, Fundeni Clinical Institute, 258, Fundeni Str., 022238 București, Romania;
| | - Leonie Eastlake
- Department of Cardiology, Lahey Hospital and Medical Center, Burlington, MA 01805, USA; (S.S.D.); (S.G.); (A.C.M.); (R.P.); (K.R.-C.)
| | - Paul Fitzpatrick
- Digital Experimental Cancer Medicine Team, Cancer Biomarker Centre, Cancer Research UK Manchester Institute, University of Manchester, Alderley Park, Macclesfield SK10 4TG, UK; (P.F.)
| | - Stephanie Foulon
- Multidisciplinary Oncology & Therapeutic Innovations Department, Aix Marseille University, CNRS, INSERM, CRCM, 13015 Marseille, France
- Oncology Department, University Hospitals of Leicester NHS Trust, Leicester LE1 5WW, UK; (E.D.); (S.K.); (A.T.)
| | - Henrik Frederiksen
- Department of Medical Oncology, University Hospitals Plymouth NHS Trust, Derriford Road, Plymouth PL6 8DH, Devon, UK;
| | - Sarju Ganatra
- Cancer Sciences Academic Unit, University Hospital Southampton NHS Foundation Trust, Tremona Road, Southampton SO16 6YD, UK; (E.C.); (H.M.)
| | - Spyridon Gennatas
- Biostatistics and Epidemiology Office, Gustave Roussy, University Paris-Saclay, 94805 Villejuif, France
| | - Andreas Glenthøj
- Department of Haematology, Odense University Hospital, 5000 Odense, Denmark;
| | - Fabio Gomes
- Department of Medical Oncology, Hospital Universitario Infanta Leonor, Av. Gran Vía del Este, 80, 28031 Madrid, Spain; (J.R.); (B.O.)
| | - Donna M. Graham
- Department of Computer Science, University of Manchester, Oxford Road, Manchester M13 9PL, UK; (O.W.); (A.F.)
- Department of Medical Oncology, Hospital Universitario Infanta Leonor, Av. Gran Vía del Este, 80, 28031 Madrid, Spain; (J.R.); (B.O.)
| | - Christina Hague
- Department of Medical Oncology, Hospital Universitario Infanta Leonor, Av. Gran Vía del Este, 80, 28031 Madrid, Spain; (J.R.); (B.O.)
| | - Kevin Harrington
- Biostatistics and Epidemiology Office, Gustave Roussy, University Paris-Saclay, 94805 Villejuif, France
- Department of Medical Oncology, The Royal Marsden NHS Foundation Trust, Fulham Road, London SW3 6JJ, UK; (S.G.); (K.H.)
| | - Michelle Harrison
- Department of Haematology, Copenhagen University Hospital—Rigshospitalet, 2100 Copenhagen, Denmark;
| | - Laura Horsley
- Department of Medical Oncology, Hospital Universitario Infanta Leonor, Av. Gran Vía del Este, 80, 28031 Madrid, Spain; (J.R.); (B.O.)
| | - Richard Hoskins
- The Institute of Cancer Research NIHR Biomedical Research Centre, London SW3 6JB, UK
| | - Zoe Hudson
- Ninewells Hospital and Medical School, Dundee DD2 1SG, UK;
| | - Lasse H. Jakobsen
- Research IT, University of Manchester, Oxford Road, Manchester M13 9PL, UK;
| | - Nalinie Joharatnam-Hogan
- Bristol Haematology and Oncology Centre, University Hospitals Bristol NHS Foundation Trust, Bristol BS2 8ED, UK; (Z.H.); (T.R.)
- Department of Haematology, Clinical Cancer Research Center, Aalborg University Hospital, 9000 Aalborg, Denmark;
| | - Sam Khan
- Medical Oncology Department, Fundeni Clinical Institute, 258, Fundeni Str., 022238 București, Romania;
| | - Umair T. Khan
- Drug Development Department (DITEP), Gustave Roussy—Cancer Campus, 94805 Villejuif, France; (A.B.); (B.B.); (C.M.)
- Department of Medical Oncology, University College London Hospitals NHS Foundation Trust, 235 Euston Road, London NW1 2BU, UK; (N.J.-H.); (K.K.)
| | - Khurum Khan
- Bristol Haematology and Oncology Centre, University Hospitals Bristol NHS Foundation Trust, Bristol BS2 8ED, UK; (Z.H.); (T.R.)
| | - Alexandra Lewis
- Department of Medical Oncology, Hospital Universitario Infanta Leonor, Av. Gran Vía del Este, 80, 28031 Madrid, Spain; (J.R.); (B.O.)
| | - Christophe Massard
- Division of Molecular and Clinical Medicine, Ninewells School of Medicine, University of Dundee, Dundee DD2 1SY, UK;
| | - Alec Maynard
- Department of Medical Oncology, Gustave Roussy, 94805 Villejuif, France; (L.A.); (F.B.)
| | - Hayley McKenzie
- NOVA National School of Public Health, Av. Padre Cruz, 1600-560 Lisboa, Portugal
| | - Olivier Michielin
- MRC Clinical Trials Unit, University College London, Gower St., London WC1E 6BT, UK
| | - Anne C. Mosenthal
- Cancer Sciences Academic Unit, University Hospital Southampton NHS Foundation Trust, Tremona Road, Southampton SO16 6YD, UK; (E.C.); (H.M.)
| | - Berta Obispo
- Cancer Research UK Manchester Institute, Cancer Biomarker Centre, The University of Manchester, Al-derley Park, Macclesfield SK10 4TG, UK; (C.Z.); (C.D.)
| | - Carlo Palmieri
- Drug Development Department (DITEP), Gustave Roussy—Cancer Campus, 94805 Villejuif, France; (A.B.); (B.B.); (C.M.)
- Department of Medical Oncology, University College London Hospitals NHS Foundation Trust, 235 Euston Road, London NW1 2BU, UK; (N.J.-H.); (K.K.)
| | - Rushin Patel
- Cancer Sciences Academic Unit, University Hospital Southampton NHS Foundation Trust, Tremona Road, Southampton SO16 6YD, UK; (E.C.); (H.M.)
| | - George Pentheroudakis
- Department of Medical Oncology, The Clatterbridge Cancer Centre NHS Foundation Trust, 65 Pembroke Place, Liverpool L7 8YA, UK; (T.B.); (U.T.K.); (C.P.)
| | - Solange Peters
- Department of Medical Oncology, The Clatterbridge Cancer Centre NHS Foundation Trust, 65 Pembroke Place, Liverpool L7 8YA, UK; (T.B.); (U.T.K.); (C.P.)
- Institute of Systems, Molecular and Integrative Biology, The University of Liverpool, Liverpool L69 3BX, UK
| | - Kimberly Rieger-Christ
- Cancer Sciences Academic Unit, University Hospital Southampton NHS Foundation Trust, Tremona Road, Southampton SO16 6YD, UK; (E.C.); (H.M.)
| | - Timothy Robinson
- Ninewells Hospital and Medical School, Dundee DD2 1SG, UK;
- Department of Oncology, Melanoma Clinic, Swiss Institute of Bioinformatics, Quartier Sorge—Batiment Amphipole, 1015 Lausanne, Switzerland;
| | - Emanuela Romano
- Medical Oncology, Centre Hospitalier Universitaire Vaudois, Rue du Bugnon 46, 1011 Lausanne, Switzerland
| | - Michael Rowe
- Population Health Sciences, University of Bristol, Oakfield House, Oakfield Grove, Bristol BS8 2BN, UK
| | - Marina Sekacheva
- Department of Oncology, Institut Curie, PSL Research University, Office 2A-5, 26, Rue d’Ulm, 75005 Paris, France;
| | - Roseleen Sheehan
- Department of Medical Oncology, Gustave Roussy, 94805 Villejuif, France; (L.A.); (F.B.)
| | - Alexander Stockdale
- Sunrise Centre, Royal Cornwall Hospitals NHS Trust, Truro TR1 3LJ, Cornwall, UK;
| | - Anne Thomas
- Medical Oncology Department, Fundeni Clinical Institute, 258, Fundeni Str., 022238 București, Romania;
- World-Class Research Center “Digital Biodesign and Personalized Healthcare”, Sechenov First Moscow State Medical University, 119991 Moscow, Russia;
| | - Lance Turtle
- Sunrise Centre, Royal Cornwall Hospitals NHS Trust, Truro TR1 3LJ, Cornwall, UK;
| | - David Viñal
- Tropical and Infectious Diseases Unit, Royal Liverpool University Hospital, 3Z Link, Prescot Street, Liverpool L7 8XP, UK; (A.S.); (L.T.)
| | - Jamie Weaver
- Department of Computer Science, University of Manchester, Oxford Road, Manchester M13 9PL, UK; (O.W.); (A.F.)
- Department of Medical Oncology, Hospital Universitario Infanta Leonor, Av. Gran Vía del Este, 80, 28031 Madrid, Spain; (J.R.); (B.O.)
| | - Sophie Williams
- Department of Medical Oncology, Gustave Roussy, 94805 Villejuif, France; (L.A.); (F.B.)
| | - Caroline Wilson
- Department of Medical Oncology, Gustave Roussy, 94805 Villejuif, France; (L.A.); (F.B.)
| | - Caroline Dive
- Digital Experimental Cancer Medicine Team, Cancer Biomarker Centre, Cancer Research UK Manchester Institute, University of Manchester, Alderley Park, Macclesfield SK10 4TG, UK; (P.F.)
| | - Donal Landers
- Digital Experimental Cancer Medicine Team, Cancer Biomarker Centre, Cancer Research UK Manchester Institute, University of Manchester, Alderley Park, Macclesfield SK10 4TG, UK; (P.F.)
| | - Timothy Cooksley
- Department of Medical Oncology, Hospital Universitario Infanta Leonor, Av. Gran Vía del Este, 80, 28031 Madrid, Spain; (J.R.); (B.O.)
| | - André Freitas
- Department of Computer Science, University of Manchester, Oxford Road, Manchester M13 9PL, UK; (O.W.); (A.F.)
- Digital Experimental Cancer Medicine Team, Cancer Biomarker Centre, Cancer Research UK Manchester Institute, University of Manchester, Alderley Park, Macclesfield SK10 4TG, UK; (P.F.)
- Leicester Cancer Research Centre, The University of Leicester, University Road, Leicester LE1 7RH, UK
| | - Anne C. Armstrong
- Department of Computer Science, University of Manchester, Oxford Road, Manchester M13 9PL, UK; (O.W.); (A.F.)
- Department of Medical Oncology, Hospital Universitario Infanta Leonor, Av. Gran Vía del Este, 80, 28031 Madrid, Spain; (J.R.); (B.O.)
| | - Rebecca J. Lee
- Department of Computer Science, University of Manchester, Oxford Road, Manchester M13 9PL, UK; (O.W.); (A.F.)
- Department of Medical Oncology, Hospital Universitario Infanta Leonor, Av. Gran Vía del Este, 80, 28031 Madrid, Spain; (J.R.); (B.O.)
| | | |
Collapse
|
9
|
Castelo-Branco L, Tsourti Z, Gennatas S, Rogado J, Sekacheva M, Viñal D, Lee R, Croitoru A, Vitorino M, Khallaf S, Šušnjar S, Soewoto W, Cardeña A, Djerouni M, Rossi M, Alonso-Gordoa T, Ngelangel C, Whisenant JG, Choueiri TK, Dimopoulou G, Pradervand S, Arnold D, Harrington K, Michielin O, Dafni U, Pentheroudakis G, Peters S, Romano E. COVID-19 in patients with cancer: first report of the ESMO international, registry-based, cohort study (ESMO-CoCARE). ESMO Open 2022; 7:100499. [PMID: 35644101 PMCID: PMC9080222 DOI: 10.1016/j.esmoop.2022.100499] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2022] [Revised: 04/22/2022] [Accepted: 04/23/2022] [Indexed: 12/19/2022] Open
Abstract
BACKGROUND ESMO COVID-19 and CAncer REgistry (ESMO-CoCARE) is an international collaborative registry-based, cohort study gathering real-world data from Europe, Asia/Oceania and Africa on the natural history, management and outcomes of patients with cancer infected with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). PATIENTS AND METHODS ESMO-CoCARE captures information on patients with solid/haematological malignancies, diagnosed with coronavirus disease 2019 (COVID-19). Data collected since June 2020 include demographics, comorbidities, laboratory measurements, cancer characteristics, COVID-19 clinical features, management and outcome. Parameters influencing COVID-19 severity/recovery were investigated as well as factors associated with overall survival (OS) upon SARS-CoV-2 infection. RESULTS This analysis includes 1626 patients from 20 countries (87% from 24 European, 7% from 5 North African, 6% from 8 Asian/Oceanian centres), with COVID-19 diagnosis from January 2020 to May 2021. Median age was 64 years, with 52% of female, 57% of cancer stage III/IV and 65% receiving active cancer treatment. Nearly 64% patients required hospitalization due to COVID-19 diagnosis, with 11% receiving intensive care. In multivariable analysis, male sex, older age, Eastern Cooperative Oncology Group (ECOG) performance status ≥2, body mass index (BMI) <25 kg/m2, presence of comorbidities, symptomatic disease, as well as haematological malignancies, active/progressive cancer, neutrophil-to-lymphocyte ratio (NLR) ≥6 and OnCovid Inflammatory Score ≤40 were associated with COVID-19 severity (i.e. severe/moderate disease requiring hospitalization). About 98% of patients with mild COVID-19 recovered, as opposed to 71% with severe/moderate disease. Advanced cancer stage was an additional adverse prognostic factor for recovery. At data cut-off, and with median follow-up of 3 months, the COVID-19-related death rate was 24.5% (297/1212), with 380 deaths recorded in total. Almost all factors associated with COVID-19 severity, except for BMI and NLR, were also predictive of inferior OS, along with smoking and non-Asian ethnicity. CONCLUSIONS Selected patient and cancer characteristics related to sex, ethnicity, poor fitness, comorbidities, inflammation and active malignancy predict for severe/moderate disease and adverse outcomes from COVID-19 in patients with cancer.
Collapse
Affiliation(s)
- L Castelo-Branco
- Scientific and Medical Division, ESMO (European Society for Medical Oncology), Lugano, Switzerland; NOVA National School of Public Health, NOVA University, Lisbon, Portugal
| | - Z Tsourti
- Frontier Science Foundation-Hellas, Athens, Greece
| | - S Gennatas
- Medical Oncology Department, The Royal Marsden Hospital - NHS Foundation Trust, London, UK
| | - J Rogado
- Medical Oncology Department, Hospital Universitario Infanta Leonor, Madrid, Spain
| | - M Sekacheva
- World-Class Research Center 'Digital Biodesign and Personalized Healthcare', Sechenov First Moscow State Medical University, Moscow, Russia
| | - D Viñal
- Medical Oncology Department, Hospital Universitario La Paz, Madrid, Spain
| | - R Lee
- Medical Oncology Department, The University of Manchester, Manchester, UK; The Christie NHS Foundation Trust, Manchester, UK
| | - A Croitoru
- Medical Oncology Department, Fundeni Clinical Institute, Bucharest, Romania
| | - M Vitorino
- Servico Oncologia, Hospital Prof. Dr Fernando Fonseca EPE (Hospital Amadora/Sintra), Amadora, Portugal
| | - S Khallaf
- Medical Oncology Department, South Egypt Cancer Institute (SECI), Assiut University, Assiut, Egypt
| | - S Šušnjar
- Department of Medical Oncology, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia
| | - W Soewoto
- Department of Surgery, Oncology Division, Sebelas Maret University, Surakarta, Indonesia
| | - A Cardeña
- Medical Oncology Department, Hospital Universitario Fundación Alcorcón, Madrid, Spain
| | - M Djerouni
- Oncology Department, Dr Saadane Hospital, Biskra, Algeria
| | - M Rossi
- Oncology Deparment, ASO 'SS. Antonio, Biagio e Cesare Arrigo', Alessandria, Italy
| | - T Alonso-Gordoa
- Medical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain
| | - C Ngelangel
- Asian Cancer Institute - Asian Hospital and Medical Center, Metro Manila, the Philippines
| | - J G Whisenant
- Vanderbilt University Medical Center, Nashville, USA
| | - T K Choueiri
- The Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, USA; Harvard Medical School, Boston, USA
| | - G Dimopoulou
- Frontier Science Foundation-Hellas, Athens, Greece
| | - S Pradervand
- Oncology Department, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland
| | - D Arnold
- Oncology, Haematology, Palliative Care Department, Asklepios Klinik Altona - Asklepios Kliniken, Hamburg, Germany
| | - K Harrington
- Division of Radiotherapy and Imaging, The Royal Marsden/The Institute of Cancer Research NIHR Biomedical Research Centre, London, UK
| | - O Michielin
- Oncology Department, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland
| | - U Dafni
- Laboratory of Biostatistics, School of Health Sciences, National and Kapodistrian University of Athens, Athens Frontier Science Foundation-Hellas, Athens, Greece
| | - G Pentheroudakis
- Scientific and Medical Division, ESMO (European Society for Medical Oncology), Lugano, Switzerland
| | - S Peters
- Department, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland
| | - E Romano
- Center for Cancer Immunotherapy, Department of Oncology, PSL Research University, Institut Curie, Paris, France.
| |
Collapse
|
10
|
Stroie T, Preda C, Meianu C, Croitoru A, Gheorghe L, Gheorghe C, Diculescu M. Health-Related Quality of Life in Patients with Inflammatory Bowel Disease in Clinical Remission: What Should We Look For? Medicina (Kaunas) 2022; 58:medicina58040486. [PMID: 35454325 PMCID: PMC9028218 DOI: 10.3390/medicina58040486] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 02/20/2022] [Revised: 03/20/2022] [Accepted: 03/25/2022] [Indexed: 12/07/2022]
Abstract
Background and Objectives: Inflammatory bowel diseases (IBD) are chronic conditions with an unpredictable evolution that can have a negative impact on patients’ quality of life (QoL). Even though patients in remission have a better QoL compared to patients with active disease, they still have a lower QoL compared to healthy people. The aim of this study is to identify the factors that are associated with a lower QoL in patients with IBD in clinical remission, in a tertiary IBD center in Romania. Materials and Methods: Ninety-seven adult patients with a current diagnosis of IBD for over 3 months who were in clinical remission were enrolled in this study. Pregnant women, patients with ostomy, perianal disease, extraintestinal manifestations or other significant comorbidities were excluded. Out of the 97 patients, 63.9% were men. The median age was 39 years (IQR 29−47), and the median disease duration was 5 years (IQR 2−10). Disease activity was assessed using the SCCAI score for ulcerative colitis and HBI score for Crohn’s disease. Remission was defined for SCCAI score ≤ 1 and HBI score ≤ 4. The health-related quality of life (HR-QoL) was assessed using the IBDQ32 score. FACIT-Fatigue was used to evaluate the level of fatigue. Patients with symptoms of anxiety or depression were identified with the HADS score. Symptoms of anxiety were considered when HADS-A >7 points and symptoms of depression when HADS-D >7 points. Results: Sixty-five patients (67%) were diagnosed with CD and the remaining 32 (33%) with UC. Ninety-three patients (95.9%) were on biological therapy. The mean IBDQ score (total score) was 190.54 points (SD +/− 8.2). The mean FACIT Fatigue score was 42.5 (SD +/− 8.2), with 6.2% of patients suffering from severe fatigue (FACIT Fatigue < 30 points). A total of 33% of patients had symptoms of anxiety and 16.5% of depression. Exposure to more than one biologic therapy (p = 0.02), fatigue (p < 0.001) and symptoms of anxiety (p < 0.001) were associated with a lower HR-QoL in the multivariate analysis. Female patients, patients with Crohn’s disease, patients with anemia and patients with symptoms of depression also had a lower HR-QoL, but this did not reach statistical significance in our study. Conclusions: Exposure to a higher number of biological agents (patients that switched multiple biologics), the presence of fatigue and symptoms of anxiety impair the HR-QoL of patients with IBD in clinical remission. Further studies should assess in a prospective manner whether early identification of these factors with prompt clinical interventions could lead to a better HR-QoL in these patients.
Collapse
Affiliation(s)
- Tudor Stroie
- Faculty of Medicine, “Carol Davila” University of Medicine and Pharmacy, 050474 Bucharest, Romania; (C.P.); (C.M.); (L.G.); (C.G.); (M.D.)
- Department of Gastroenterology, Fundeni Clinical Institute, 022328 Bucharest, Romania
- Correspondence:
| | - Carmen Preda
- Faculty of Medicine, “Carol Davila” University of Medicine and Pharmacy, 050474 Bucharest, Romania; (C.P.); (C.M.); (L.G.); (C.G.); (M.D.)
- Department of Gastroenterology, Fundeni Clinical Institute, 022328 Bucharest, Romania
| | - Corina Meianu
- Faculty of Medicine, “Carol Davila” University of Medicine and Pharmacy, 050474 Bucharest, Romania; (C.P.); (C.M.); (L.G.); (C.G.); (M.D.)
- Department of Gastroenterology, Fundeni Clinical Institute, 022328 Bucharest, Romania
| | - Adina Croitoru
- Faculty of Medicine, “Titu Maiorescu” University, 031593 Bucharest, Romania;
- Department of Oncology, Fundeni Clinical Institute, 022328 Bucharest, Romania
| | - Liana Gheorghe
- Faculty of Medicine, “Carol Davila” University of Medicine and Pharmacy, 050474 Bucharest, Romania; (C.P.); (C.M.); (L.G.); (C.G.); (M.D.)
- Department of Gastroenterology, Fundeni Clinical Institute, 022328 Bucharest, Romania
| | - Cristian Gheorghe
- Faculty of Medicine, “Carol Davila” University of Medicine and Pharmacy, 050474 Bucharest, Romania; (C.P.); (C.M.); (L.G.); (C.G.); (M.D.)
- Department of Gastroenterology, Fundeni Clinical Institute, 022328 Bucharest, Romania
| | - Mircea Diculescu
- Faculty of Medicine, “Carol Davila” University of Medicine and Pharmacy, 050474 Bucharest, Romania; (C.P.); (C.M.); (L.G.); (C.G.); (M.D.)
- Department of Gastroenterology, Fundeni Clinical Institute, 022328 Bucharest, Romania
| |
Collapse
|
11
|
Botea F, Barcu A, Croitoru A, Tomescu D, Lupescu I, Dumitru R, Herlea V, Verdea C, Becker T, Popescu I, Linecker M. Parenchyma Sparing ALPPS - Ultrasound Guided Partition Through Segment 4 to Maximize Resectability (with video). Chirurgia (Bucur) 2022. [PMID: 35272758 DOI: 10.21614/chirurgia.2652.online.ahead.of.print.nov30] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
Background: Associating liver partition and portal vein ligation (ALPPS) has evolved as a treatment strategy for patients with liver tumors who are not amenable for upfront hepatectomy because of an insufficient future liver remnant (FLR). Aim of this study was to test the applicability of ultrasound guided parenchyma sparing surgery to ALPPS concept, by non-anatomically shifting the plane of transection in favor of FLR, resulting in a new technical variant of ALPPS, entitled parenchyma sparing ALPPS (psALPPS). Materials and Methods: Patients who could not safely undergo right trisectionectomy ALPPS because of insufficient FLR were considered eligible for psALPPS, consisting in liver partition through segment 4 using ultrasound guidance. Results: Between April 2017 and April 2021, five patients with median age of 68 years (range: 66-78), four male and one female, underwent psALPPS for colorectal liver metastases (N=2), intrahepatic cholangiocarcinoma (N=2), and hepatocellular carcinoma (N=1). Standardized FLR (sFLR) for segments 2-3 before stage 1 surgery would have been a median of 11.6%. PsALPPS could double the sFLR at stage 1 resulting in an increase of ps-sFLR from a median of 22.7% (at stage 1) to 34.0% (at stage 2) after a median interstage interval of 15 days. All patients tolerated surgery well and no major complications were recorded. Conclusions: Applying the principles of parenchyma sparing surgery to ALPPS offers the advantage to maximize FLR and simultaneously reduce ischemic injury of segment 4 compared to conventional ALPPS. In this way, psALPPS may markedly increase resectability while reducing morbidity.
Collapse
|
12
|
Botea F, Barcu A, Croitoru A, Tomescu D, Lupescu I, Dumitru R, Herlea V, Verdea C, Becker T, Popescu I, Linecker M. Parenchyma Sparing ALPPS Ultrasound Guided Partition Through Segment 4 to Maximize Resectability (with video). Chirurgia (Bucur) 2022; 117:81-93. [PMID: 34915689 DOI: 10.21614/chirurgia.2652] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/01/2022] [Indexed: 11/23/2022]
Abstract
Background Associating liver partition and portal vein ligation (ALPPS) has evolved as a treatment strategy for patients with liver tumors who are not amenable for upfront hepatectomy because of an insufficient future liver remnant (FLR). Aim of this study was to test the applicability of ultrasound guided parenchyma sparing surgery to ALPPS concept, by non-anatomically shifting the plane of transection in favor of FLR, resulting in a new technical variant of ALPPS, entitled parenchyma sparing ALPPS (psALPPS). Materials and Methods Patients who could not safely undergo right trisectionectomy ALPPS because of insufficient FLR were considered eligible for psALPPS, consisting in liver partition through segment 4 using ultrasound guidance. Results Between April 2017 and April 2021, five patients with median age of 68 years (range: 66-78), four male and one female, underwent psALPPS for colorectal liver metastases (N=2), intrahepatic cholangiocarcinoma (N=2), and hepatocellular carcinoma (N=1). Standardized FLR (sFLR) for segments 2-3 before stage 1 surgery would have been a median of 11.6%. PsALPPS could double the sFLR at stage 1 resulting in an increase of ps-sFLR from a median of 22.7% (at stage 1) to 34.0% (at stage 2) after a median interstage interval of 15 days. All patients tolerated surgery well and no major complications were recorded. Conclusions Applying the principles of parenchyma sparing surgery to ALPPS offers the advantage to maximize FLR and simultaneously reduce ischemic injury of segment 4 compared to conventional ALPPS. In this way, psALPPS may markedly increase resectability while reducing morbidity. Video https://www.revistachirurgia.ro/pdfs/?EntryID=922974&art=2021-parenchyma-sparing-ALPPS-ultrasound-guided-partition.pdf
Collapse
|
13
|
Kraft A, Croitoru A, Moldovan C, Lupescu I, Tomescu D, Purnichescu-Purtan R, Herlea V, Popescu I, Botea F. Is Long-Term Survival in Metastases from Neuroendocrine Neoplasms Improved by Liver Resection? Medicina (Kaunas) 2021; 58:medicina58010022. [PMID: 35056330 PMCID: PMC8778622 DOI: 10.3390/medicina58010022] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/08/2021] [Revised: 12/17/2021] [Accepted: 12/22/2021] [Indexed: 12/13/2022]
Abstract
Background and Objectives: Although many of the neuroendocrine neoplasms (NEN) have a typically prolonged natural history compared with other gastrointestinal tract cancers, at least 40% of patients develop liver metastases. This study aims to identify whether liver resection improves the overall survival of patients with liver metastases from NEN. Materials and Methods: We conducted a retrospective study at “Fundeni” Clinical Institute over a time period of 15 years; we thereby identified a series of 93 patients treated for NEN with liver metastases, which we further divided into 2 groups as follows: A (45 patients) had been subjected to liver resection complemented by systemic therapies, and B (48 patients) underwent systemic therapy alone. To reduce the patient selection bias we performed at first a propensity score matching. This was followed by a bootstrapping selection with Jackknife error correction, with the purpose of getting a statistically illustrative sample. Results: The overall survival of the matched virtual cohort under study was 41 months (95% CI 37–45). Group A virtual matched patients showed a higher survival rate (52 mo., 95% CI: 45–59) than B (31 mo., 95% CI: 27–35), (p < 0.001, Log-Rank test). Upon multivariate analysis, seven independent factors were identified to have an influence on survival: location (midgut) and primary tumor grading (G3), absence of concomitant LM, number (2–4), location (unilobar), grading (G3) of LM, and 25–50% hepatic involvement at the time of the metastatic disease diagnosis. Conclusions: Hepatic resection is nowadays the main treatment providing potential cure and prolonged survival, for patients with NEN when integrated in a multimodal strategy based on systemic therapy.
Collapse
Affiliation(s)
- Alin Kraft
- Doctoral School in Medicine, “Titu Maiorescu” University, 040441 Bucharest, Romania;
- Department of General Surgery, “Regina Maria” Military Emergency Hospital, 500007 Brașov, Romania
| | - Adina Croitoru
- Department of Oncology, “Fundeni” Clinical Institute, 022328 Bucharest, Romania;
- Faculty of Medicine, “Titu Maiorescu” University, 031593 Bucharest, Romania; (C.M.); (V.H.); (I.P.)
| | - Cosmin Moldovan
- Faculty of Medicine, “Titu Maiorescu” University, 031593 Bucharest, Romania; (C.M.); (V.H.); (I.P.)
| | - Ioana Lupescu
- Radiology and Medical Imaging Department, Fundeni Clinical Institute, “Carol Davila” University of Medicine and Pharmacy, 050474 Bucharest, Romania; (I.L.); (D.T.)
- Department of Radiology and Medical Imaging, “Fundeni” Clinical Institute, 022328 Bucharest, Romania
| | - Dana Tomescu
- Radiology and Medical Imaging Department, Fundeni Clinical Institute, “Carol Davila” University of Medicine and Pharmacy, 050474 Bucharest, Romania; (I.L.); (D.T.)
- Department of Anaesthesia and Intensive Care, “Fundeni” Clinical Institute, 022328 Bucharest, Romania
| | - Raluca Purnichescu-Purtan
- Faculty of Applied Sciences, Department of Mathematical Methods and Models, University Politehnica of Bucharest, 060042 Bucharest, Romania;
| | - Vlad Herlea
- Faculty of Medicine, “Titu Maiorescu” University, 031593 Bucharest, Romania; (C.M.); (V.H.); (I.P.)
- Department of Pathology, “Fundeni” Clinical Institute, 022328 Bucharest, Romania
| | - Irinel Popescu
- Faculty of Medicine, “Titu Maiorescu” University, 031593 Bucharest, Romania; (C.M.); (V.H.); (I.P.)
- “Dan Setlacec” Center for General Surgery and Liver Transplant, “Fundeni” Clinical Institute, 022328 Bucharest, Romania
| | - Florin Botea
- Faculty of Medicine, “Titu Maiorescu” University, 031593 Bucharest, Romania; (C.M.); (V.H.); (I.P.)
- “Dan Setlacec” Center for General Surgery and Liver Transplant, “Fundeni” Clinical Institute, 022328 Bucharest, Romania
- Correspondence:
| |
Collapse
|
14
|
Bârcu A, Kraft A, Verdea C, Croitoru A, Lupescu I, Tomescu D, Popescu I, Botea F. En-Bloc Complete Segment 1 Resection and Left Hepatectomy for Klatskin Tumor. Chirurgia (Bucur) 2021; 116:634-638. [PMID: 34749860 DOI: 10.21614/chirurgia.116.5.634] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/01/2021] [Indexed: 11/23/2022]
Abstract
video width="640" height="480" controls controlsList="nodownload" poster="https://www.revistachirurgia.ro/pdfs/video/Complete_segment_resection_hepatectomy_klatskin_tumor.jpg" style="margin-top: -20px;" source src="https://www.revistachirurgia.ro/pdfs/video/Complete_segment_resection_hepatectomy_klatskin_tumor.mp4" type="video/mp4" Your browser does not support the video tag. /video We present the case of a 37-year-old male patient with no significant history, hospitalized in our center for painless jaundice with sudden onset. CT contrast portal phase imaging revealed a tumor located at the main biliary confluence, in the proximity of the main portal bifurcation, with no venous or arterial vascular invasion, nor extrahepatic metastases. MRCP diagnosed a Bismuth- Corlette type Klatskin IIIb tumor. For complete assessment of biliary involvement and surgical planning, in addition to the Bismuth-Corlette classification, we took into consideration the presence of infiltration of the bile ducts for segment 1, documented at MRCP. Therefore, a left hepatectomy with en-bloc complete segment 1 resection, along with the main bile ducts and hilar lymphadenectomy, was considered best suited for achieving curative resection in this case. After an uneventful postoperative course, the patient was discharged in the 12th postoperative day. Currently, the patient is disease-free after 84 months. We consider that the long-term recurrence free survival was favored by the complete segment 1 resection. Therefore, for complete assessment of biliary involvement in Klatskin tumor, we recommend that in addition to Bismuth-Corlette classification, infiltration of the bile duct for segment 1 should always be evaluated. If present, the entire segment 1 should be removed for best oncological results.
Collapse
|
15
|
Kraft A, Croitoru A, Gheorghe C, Lupescu I, Grasu M, Tomescu D, Droc G, Herlea V, Barcu A, Popescu I, Botea F. Liver Resection for Metastases from Gastrointestinal Stromal Tumors: Does it Improve Long-Term Survival? Chirurgia (Bucur) 2021; 116:438-450. [PMID: 34498563 DOI: 10.21614/chirurgia.116.4.438] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/01/2021] [Indexed: 11/23/2022]
Abstract
BACKGROUND AIMS The emergence of tyrosine kinase inhibitors, radically altered the management of GISTs and sparked controversy regarding the role of hepatic resection for metastatic tumors. This study aims to identify whether there is improvement in the overall survival of patients with gastrointestinal liver metastases, undergoing hepatic resection in the context of multimodal treatment strategy, as to those approached only by systemic therapy. Methods: Using a retrospective database, we identified 57 patients treated at our center over a 12-year period: Group A (n=31) underwent hepatic resection alongside systemic therapies, and B (n=26) only systemic therapies. In order to obtain a more robust sample, needed for the survival analysis, we performed a propensity score matching and a bootstrapping selection with Jackknife correction for errors; thus, we created an extended sample of 1000 virtual patients. Results: The overall survival measured in all patients was 47 months (95%CI:34-60); significantly higher for group A (56 months, 95%CI:37-75) compared to group B (38 months, 95%CI:19-56), (p=0.007, Log Rank test). Multivariate analysis identified one risk factor: the presence synchronous liver metastases upon diagnosis of primary. Conclusions: Liver resection following TKI therapy is the current mainstay of treatment strategy for potential cure and prolonged survival, in appropriately selected patients evaluated in an multidisciplinary tumor board.
Collapse
|
16
|
Kraft A, Bârcu A, Croitoru A, Lupescu I, Tomescu D, Popescu I, Botea F. Resection of Giant Liver Metastasis of Gastrointestinal Stromal Tumor Using Intraoperative Ultrasound Guidance. Chirurgia (Bucur) 2021; 116:506-509. [PMID: 34498575 DOI: 10.21614/chirurgia.116.4.506] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/01/2021] [Indexed: 11/23/2022]
Abstract
We present the case of a 37-year-old patient with a surgical history of a gastrointestinal stromal tumor with jejunal location, AFIP classification 6a, hospitalized in our center for synchronous liver metastases. The oncological assessment performed after 12 months from surgery for primary tumor, during which Imatinib was administered, reveals stable disease. CT scan showed a single very large centrally located liver metastasis, 14 cm in diameter, involving segments V and VIII IV, IV and VII, compressing the main portal bifurcation, right hepatic vein, umbilical (scizural) vein and left hepatic vein, invading the middle hepatic vein. We considered it feasible to apply the concept of R1 vascular resection, performing a limited, non-anatomical, ultrasound-guided central hepatectomy, allowing detachment of the tumor from the right hepatic vein and from the umbilical vein. Thus, we sacrificed only the ventral portal pedicles of segments V and VIII and partially preserved these segments to avoid the risk of post-resection liver failure.Currently, the patient is disease-free after 53 months, supporting the concept of ultrasound-guided R1 vascular resection, in the context of systemic therapy with tyrosine kinase inhibitors for metastases of stromal gastrointestinal tumors. (video article https://www.revistachirurgia.ro/pdfs/video/Liver-Resection-Metastases-Stromal-Tumors-2283.mp4).
Collapse
|
17
|
Lungulescu CV, Ungureanu BS, Turcu-Stiolica A, Ghimpau V, Artene SA, Cazacu IM, Grecu AF, Dinescu VC, Croitoru A, Volovat SR. The role of IgE specific for galactose-α-1,3-galactose in predicting cetuximab induced hypersensitivity reaction: a systematic review and a diagnostic meta-analysis. Sci Rep 2020; 10:21355. [PMID: 33288791 PMCID: PMC7721698 DOI: 10.1038/s41598-020-78497-7] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2020] [Accepted: 11/26/2020] [Indexed: 02/01/2023] Open
Abstract
Recombinant monoclonal antibodies are used for treating various diseases, from asthma, rheumatoid arthritis, and inflammatory bowel disease to cancer. Although monoclonal antibodies are known to have fewer toxic reactions compared with the conventional cytotoxic antineoplastic drugs, the cases of severe systemic hypersensitivity reaction (HSR) should be acknowledged. Our aim was to assess the diagnostic accuracy of the anti-IgE for galactose-α-1,3-galactose in patients with HSRs to cetuximab. We searched in PubMed, Cochrane Library, Scopus, and World of Science databases to July 1st, 2020. We included a total of 6 studies, with 1074 patients. Meta-analysis was performed using bivariate analysis and the random-effect model. The pooled sensitivity was 73% (95% CI 62-81%) and the pooled specificity was 88% (95% CI 79-94%). We had not found significant heterogeneity and, despite some discrepancies in the nature of data available in the analysed studies, we draw the conclusion that the presence of cetuximab specific IgE (anti cetuximab antibody) and/or galactose-α-1,3-galactose shows moderate to high sensitivity and specificity of developing an HSR. More studies are needed to establish a protocol necessary for the proper prediction and avoidance of HSR related to cetuximab.
Collapse
Affiliation(s)
| | - Bogdan Silviu Ungureanu
- Research Center of Gastroenterology and Hepatology, University of Medicine and Pharmacy of Craiova, Craiova, Romania.
| | - Adina Turcu-Stiolica
- Department of Pharmacoeconomics, University of Medicine and Pharmacy of Craiova, Craiova, Romania.
| | - Valentina Ghimpau
- Pharmacy of Craiova Doctoral School, University of Medicine, Craiova, Romania
| | | | | | | | - Venera Cristina Dinescu
- Health Promotion and Occupational Medicine Department, University of Medicine & Pharmacy of Craiova, Craiova, Romania
| | - Adina Croitoru
- Fundeni Clinical Institute, Titu Maiorescu University, Bucharest, Romania
| | | |
Collapse
|
18
|
Săftescu S, Popovici D, Oprean C, Negru A, Croitoru A, Zemba M, Yasar I, Preda M, Negru Ș. Endurance of erythrocyte series in chemotherapy. Exp Ther Med 2020; 20:214. [PMID: 33149778 PMCID: PMC7604759 DOI: 10.3892/etm.2020.9344] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2020] [Accepted: 09/24/2020] [Indexed: 11/12/2022] Open
Abstract
Hematopoietic bone marrow toxicity is most often the limiting factor for chemotherapy doses. Increasing the intensity of chemotherapy doses (higher doses or more frequent administration) would improve antitumor effects, but the hematological toxicity does not allow these dose increases. This study evaluated the impact of chemotherapies on the parameters belonging to the red blood cell series in the hemogram and aimed to identify some particular evolution profiles. We selected 855 evaluations performed before the administration of chemotherapy belonging to the treatments initiated during the period December 2018-February 2020, containing 5-fluorouracil, cisplatin, docetaxel, epirubicin or pemetrexed. The data of the 644 evaluations related to the cycles 1-4 of chemotherapy were subject to this processing. The average relative loss of hemoglobin is -11% after the first three cycles of treatment, with statistically significant differences in hemoglobin levels in favor of men. There are risk factors associated with higher average losses, such as age <50 years or >65 years (statistically significant), body mass index (BMI) >25, cisplatin treatment (insufficient number of cases to reach statistical significance).
Collapse
Affiliation(s)
- Sorin Săftescu
- Department of Oncology, 'Victor Babe?' University of Medicine and Pharmacy, 300041 Timisoara, Romania
| | - Dorel Popovici
- Department of Oncology, 'Victor Babe?' University of Medicine and Pharmacy, 300041 Timisoara, Romania
| | - Cristina Oprean
- Department of Oncology, 'Victor Babe?' University of Medicine and Pharmacy, 300041 Timisoara, Romania
| | - Alina Negru
- Department of Cardiology, 'Victor Babe?' University of Medicine and Pharmacy, 300041 Timisoara, Romania
| | - Adina Croitoru
- Department of Medical Oncology, Fundeni Clinical Institute, 022328 Bucharest, Romania
| | - Mihail Zemba
- Department of Ophthalmology, 'Carol Davila' University of Medicine and Pharmacy, 050474 Bucharest, Romania
| | - Ionela Yasar
- Department of Ophthalmology, 'Carol Davila' University of Medicine and Pharmacy, 050474 Bucharest, Romania
| | - Maria Preda
- Department of Ophthalmology, 'Victor Babe?' University of Medicine and Pharmacy, 300041 Timisoara, Romania
| | - Șerban Negru
- Department of Oncology, 'Victor Babe?' University of Medicine and Pharmacy, 300041 Timisoara, Romania
| |
Collapse
|
19
|
Volovat SR, Ciuleanu TE, Koralewski P, Olson JEG, Croitoru A, Koynov K, Stabile S, Cerea G, Osada A, Bobe I, Volovat C. A multicenter, single-arm, basket design, phase II study of NC-6004 plus gemcitabine in patients with advanced unresectable lung, biliary tract, or bladder cancer. Oncotarget 2020; 11:3105-3117. [PMID: 32913555 PMCID: PMC7443368 DOI: 10.18632/oncotarget.27684] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2020] [Accepted: 07/07/2020] [Indexed: 12/25/2022] Open
Abstract
NC-6004 is a nanoparticle developed using micellar technology that can improve release of cisplatin, a standard treatment for many cancer types, and achieve selective distribution to tumors. Here, in the Phase II portion of this study, the activity, safety, tolerability, and effects on quality of life of NC-6004 in combination with gemcitabine was examined in 34 squamous non-small cell lung carcinoma (NSCLC) patients, 50 biliary tract cancer patients, and 13 bladder cancer patients. All patients received 135 mg/m2 NC-6004 on day one and 1,250 mg/m2 gemcitabine on days one and eight. The median progression-free survival was 3.9 months in NSCLC patients, 4.3 months in biliary tract cancer patients, and 6.8 months in bladder cancer patients fit for cisplatin treatment. The most frequently reported Grade 3 Treatment Emergent Adverse Events across all cohorts were nausea, anemia and neutropenia, and hyponatremia. Quality of life measures for patients who received the combined therapy were generally consistent with expectations for patients undergoing chemotherapy. Overall, combined NC-6004 and gemcitabine treatment resulted in long-lasting antitumor activity and had a favorable safety profile, suggesting that it should be investigated further as a therapy for various types of cancer.
Collapse
Affiliation(s)
- Simona Ruxandra Volovat
- Department of Medicine III, Medical Oncology-Radiotherapy, Grigore T. Popa University of Medicine and Pharmacy, Iasi, Romania
| | - Tudor-Eliade Ciuleanu
- The Oncology Institue "Prof. Dr. Ion Chiricuta" Cluj-Napoca, Cluj-Napoca, Romania.,Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania
| | | | | | - Adina Croitoru
- Department of Medical Oncology, Fundeni Clinical Institute, Bucharest, Romania
| | - Krassimir Koynov
- Multiprofile Hospital for Active Treatment Serdika, Sofia, Bulgaria
| | - Stefano Stabile
- S C Oncologia Falck, Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy
| | - Giulio Cerea
- S C Oncologia Falck, Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy
| | | | | | - Constantin Volovat
- Department of Medicine III, Medical Oncology-Radiotherapy, Grigore T. Popa University of Medicine and Pharmacy, Iasi, Romania.,Center of Oncology Euroclinic, Iasi, Romania
| |
Collapse
|
20
|
Bacalbasa N, Balescu I, Vilcu M, Croitoru A, Dima S, Brasoveanu V, Brezean I, Popescu I. Pancreatoduodenectomy After Neoadjuvant Chemotherapy for Locally Advanced Pancreatic Cancer in the Presence of an Aberrant Right Hepatic Artery. In Vivo 2020; 34:401-406. [PMID: 31882506 DOI: 10.21873/invivo.11788] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2019] [Revised: 10/16/2019] [Accepted: 10/18/2019] [Indexed: 12/15/2022]
Abstract
BACKGROUND/AIM Locally advanced pancreatic head cancer remains an aggressive malignancy with a low likelihood of achieving resectability after neoadjuvant chemotherapy. Resection is even more difficult if anatomical variations of the blood supply are present. CASE REPORT We present the case of a 62-year-old male diagnosed with locally advanced pancreatic cancer in the presence of an aberrant right hepatic artery originating from the superior mesenteric artery. After completing six cycles of neoadjuvant chemotherapy consisting of irinotecan and oxaliplatin, resectability was achieved, the patient being submitted to pancreatoduodenectomy. Intraoperatively, the presence of an aberrant right hepatic artery originating from the superior mesenteric artery was confirmed. The postoperative course was uneventful, the patient being discharged on the eight postoperative day, while the histopathological studies confirmed the negativity of the resection margins. CONCLUSION Resectability can be achieved after neoadjuvant chemotherapy for locally advanced pancreatic cancer. However, attention should be focused on the possibility of the presence of anatomical variations of the pancreatic and liver blood supply.
Collapse
Affiliation(s)
- Nicolae Bacalbasa
- Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.,I. Cantacuzino Clinical Hospital, Bucharest, Romania.,Fundeni Clinical Institute - Center of Excellence in Translational Medicine, Bucharest, Romania
| | | | - Mihaela Vilcu
- Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.,I. Cantacuzino Clinical Hospital, Bucharest, Romania
| | - Adina Croitoru
- Fundeni Clinical Institute - Center of Excellence in Translational Medicine, Bucharest, Romania.,Titu Maiorescu University of Medicine and Pharmacy, Bucharest, Romania
| | - Simona Dima
- Fundeni Clinical Institute - Center of Excellence in Translational Medicine, Bucharest, Romania
| | - Vladislav Brasoveanu
- Fundeni Clinical Institute - Center of Excellence in Translational Medicine, Bucharest, Romania.,Titu Maiorescu University of Medicine and Pharmacy, Bucharest, Romania
| | - Iulian Brezean
- Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.,I. Cantacuzino Clinical Hospital, Bucharest, Romania
| | - Irinel Popescu
- Fundeni Clinical Institute - Center of Excellence in Translational Medicine, Bucharest, Romania.,Titu Maiorescu University of Medicine and Pharmacy, Bucharest, Romania
| |
Collapse
|
21
|
Bacalbasa N, Balescu I, Vilcu M, Neacsu A, Dima S, Croitoru A, Brezean I. Pelvic Exenteration for Locally Advanced and Relapsed Pelvic Malignancies - An Analysis of 100 Cases. In Vivo 2020; 33:2205-2210. [PMID: 31662557 DOI: 10.21873/invivo.11723] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2019] [Revised: 09/01/2019] [Accepted: 09/03/2019] [Indexed: 11/10/2022]
Abstract
BACKGROUND/AIM Although pelvic exenteration is an aggressive surgical procedure, it remains almost the only curative solution for patients diagnosed with large pelvic malignancies. PATIENTS AND METHODS We present a series of 100 patients submitted to pelvic exenteration with curative intent. RESULTS The origin of the primary tumor was most commonly represented by cervical cancer, followed by, endometrial cancer, rectal cancer, ovarian cancer and vulvo-vaginal cancer. An R0 resection was confirmed in 68 cases, while the remaining 32 cases presented lateral positive resection margins or perineal positive margins. The postoperative morbidity rate was 37% while the mortality rate was 3%. As for the-long term outcomes, the median overall survival time was 38.7 months, being most significantly influenced by the origin of the primary tumor. CONCLUSION Although pelvic exenteration is still associated with an increased morbidity, an important improvement in the long-term survival can be achieved, especially if radical resection is feasible.
Collapse
Affiliation(s)
- Nicolae Bacalbasa
- "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.,"I. Cantacuzino" Clinical Hospital, Bucharest, Romania.,"Fundeni" Clinical Institute - Center of Excellence in Translational Medicine, Bucharest, Romania
| | | | - Mihaela Vilcu
- "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.,"I. Cantacuzino" Clinical Hospital, Bucharest, Romania
| | - Adrian Neacsu
- "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania
| | - Simona Dima
- "Fundeni" Clinical Institute - Center of Excellence in Translational Medicine, Bucharest, Romania
| | - Adina Croitoru
- "Fundeni" Clinical Institute - Center of Excellence in Translational Medicine, Bucharest, Romania.,"Titu Maiorescu" University, Bucharest, Romania
| | - Iulian Brezean
- "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.,"I. Cantacuzino" Clinical Hospital, Bucharest, Romania
| |
Collapse
|
22
|
Bacalbasa N, Balescu I, Dima S, Croitoru A, Brasoveanu V, Vilcu M, Brezean I. Pancreatoduodenectomy En Bloc With Vascular Resections in Borderline Resectable Pancreatic Cancer. In Vivo 2020; 33:2303-2308. [PMID: 31662572 DOI: 10.21873/invivo.11738] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2019] [Revised: 09/20/2019] [Accepted: 09/23/2019] [Indexed: 02/08/2023]
Abstract
BACKGROUND/AIM Pancreatic cancer remains asymptomatic for a long period of time, being frequently diagnosed when vascular invasion is already present. Such cases are widely known as borderline lesions. The aim of this study was to identify the effectiveness of vascular resection in this subgroup of patients. PATIENTS AND METHODS Fifteen such cases were submitted to surgery with curative intent. RESULTS Eight cases were diagnosed with borderline resectable lesions with portal vein invasion and were submitted to per primam resection and seven cases were initially diagnosed with arterial invasion and had been initially submitted to neoadjuvant chemotherapy followed by resection. In all cases portal vein resection was needed while in other four cases association of superior mesenteric artery resection was performed. Postoperatively, five patients developed complications requiring reoperation, three of whom died at the end of the first postoperative month. The histopathological studies confirmed the completeness of resection in all cases. CONCLUSION Vascular resections in pancreatic cancer resections remain demanding procedures, and are reserved for cases in which a radical resection is feasible.
Collapse
Affiliation(s)
- Nicolae Bacalbasa
- "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.,"I. Cantacuzino" Clinical Hospital, Bucharest, Romania.,"Fundeni" Clinical Institute - Center of Excellence in Translational Medicine, Bucharest, Romania
| | | | - Simona Dima
- "Fundeni" Clinical Institute - Center of Excellence in Translational Medicine, Bucharest, Romania
| | - Adina Croitoru
- "Fundeni" Clinical Institute - Center of Excellence in Translational Medicine, Bucharest, Romania.,"Titu Maiorescu" University, Bucharest, Romania
| | - Vladislav Brasoveanu
- "Fundeni" Clinical Institute - Center of Excellence in Translational Medicine, Bucharest, Romania.,"Titu Maiorescu" University, Bucharest, Romania
| | - Mihaela Vilcu
- "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.,"I. Cantacuzino" Clinical Hospital, Bucharest, Romania
| | - Iulian Brezean
- "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.,"I. Cantacuzino" Clinical Hospital, Bucharest, Romania
| |
Collapse
|
23
|
Lungulescu C, Croitoru VM, Lungulescu C, Croitoru A, Paul D. DURABLE RESPONSE IN A CASE OF METASTATIC ANAPLASTIC THYROID CANCER USING A COMBINATION OF TYROSINE KINASE INHIBITORS AND A CHECK POINT INHIBITOR. Acta Endocrinol (Buchar) 2020; 16:236-241. [PMID: 33029242 DOI: 10.4183/aeb.2020.236] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Abstract
Anaplastic thyroid cancer (ATC) is a highly uncommon (less than 2% of thyroid malignancies) and aggressive type of cancer, with aggressive behavior and, therefore, exhibiting poor prognosis. ATC tumors are automatically labeled as stage IV disease regardless of standard criteria such as tumor burden or metastasis. ATC tumors require a diversified treatment approach that includes surgical resection, followed by a complete an aggressive combination of radiation and chemotherapy and/or palliative care. Despite best efforts, 1-year overall survival of patients is 20% to 40% with nearly universal mortality rate. Consequently, novel approaches (targeted therapy, immunotherapy) have been studied, alone or in combination, to improve the dire prognosis of these patients. BRAF V600E mutation is the most common genetic mutation found in ATC. We report the case of a 57-year-old man diagnosed with stage IVc (undifferentiated) ATC with hepatic and osseous metastases. The molecular analysis of the tumor revealed a V600E BRAF-mutation. The patient was treated with Dabrafenib and Trametinib, and achieved remission 5 weeks after starting the treatment. Subsequently, he had a thyroidectomy, and pembrolizumab was added to the two tyrosine kinase inhibitors. 9 months later he is still in remission. This case illustrates the importance of obtaining molecular information in anaplastic thyroid cancer and the urgent need of studies investigating the combination of tyrosine kinase inhibitors and check-point inhibitors in patients with V600E BRAF- mutations.
Collapse
Affiliation(s)
- C Lungulescu
- University of Medicine and Pharmacy of Craiova - Oncology, Bucharest, Romania
| | - V M Croitoru
- University of Medicine and Pharmacy of Craiova - Fundeni Clinical Institute - Medical Oncology, Bucharest, Romania
| | - C Lungulescu
- University of Medicine and Pharmacy of Craiova - Doctoral School, Craiova, Bucharest, Romania
| | - A Croitoru
- University of Medicine and Pharmacy of Craiova - Fundeni Clinical Institute - Medical Oncology, Bucharest, Romania.,University of Medicine and Pharmacy of Craiova - "Titu Maiorescu" University - "Acad. Nicolae Cajal" Institute of Medical Scientific Research, Bucharest, Romania
| | - D Paul
- University of Medicine and Pharmacy of Craiova - New York-Presbyterian Hospital/Weill Cornell Medical Center - Department of Medicine, Division of Hematology/Oncology, New York, United States of America
| |
Collapse
|
24
|
Bacalbasa N, Balescu I, Croitoru A, Dima S, Vilcu M, Brezean I. Is HIPEC beneficial in platinum resistant relapsed ovarian cancer? Ro J Med Pract 2019. [DOI: 10.37897/rjmp.2019.3.8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
|
25
|
Bacalbasa N, Balescu I, Croitoru A, Dima S, Vilcu M, Brezean I. Duodenal resections as part of the therapeutic strategy for duodenal malignant tumors. Ro J Med Pract 2019. [DOI: 10.37897/rjmp.2019.3.2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
|
26
|
Colita A, Colita A, Bumbea H, Croitoru A, Orban C, Lipan LE, Craciun OG, Soare D, Ghimici C, Manolache R, Gelatu I, Vladareanu AM, Pasca S, Teodorescu P, Dima D, Lupu A, Coriu D, Tomuleasa C, Tanase A. LEAM vs. BEAM vs. CLV Conditioning Regimen for Autologous Stem Cell Transplantation in Malignant Lymphomas. Retrospective Comparison of Toxicity and Efficacy on 222 Patients in the First 100 Days After Transplant, On Behalf of the Romanian Society for Bone Marrow Transplantation. Front Oncol 2019; 9:892. [PMID: 31552193 PMCID: PMC6746965 DOI: 10.3389/fonc.2019.00892] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2019] [Accepted: 08/27/2019] [Indexed: 12/13/2022] Open
Abstract
High-dose chemotherapy (HDT) followed by autologous hematopoietic stem cell transplantation (ASCT) is widely used in patients with malignant lymphomas. In Europe over 8,000 ASCTs for lymphoma were performed out of a total of 40,000 transplants according to the European Bone Marrow Transplant (EBMT) activity survey in 2017. ASCT is considered the standard treatment for eligible patients failing to achieve remission after first line chemotherapy or patients with relapsed or refractory lymphomas, including classical Hodkin's lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, and follicular lymphoma, as well as consolidation therapy in first remission in mantle cell lymphoma. BEAM (BCNU/carmustine, etoposide, cytarabine, and melphalan) is the most commonly used conditioning regimen for ASCT in patients with relapsed/refractory (R/R) lymphomas in Europe, whereas the CBV (cyclophosphamide, BCNU, and etoposide) regimen is also widely used in North America. Recently, concerns regarding BCNU toxicity as well as restricted availability of BCNU and melphalan has determined an increasing number of transplant centers to use alternative conditioning regimens. Currently, only a few comparative studies, most of them retrospective, between different conditioning protocols regarding efficacy and toxicity have been published. Thus, in the current manuscript, we report the experience of 2 transplant centers in ASCT in R/R lymphomas with three types of conditioning: BEAM, CLV (cyclophosphamide, lomustine, etoposide) and LEAM (lomustine, etoposide, cytarabine, and melphalan), with the aim to evaluate the results of alternative conditioning regimens using lomustine (LEAM and CLV) and compare them with the standard BEAM regarding early toxicity, engraftment, and transplant related mortality (TRM). All patients developed grade IV neutropenia, anemia with/without transfusion necessity. Severe thrombocytopenia with transfusion requirements is reported in most cases. Median time to platelet engraftment and neutrophil engraftment was 13 days (range) and 10 days (range), respectively. Gastrointestinal toxicity was the most common non-hematologic toxicity after all three conditioning regimens. Oral mucositis in various grades from I to IV was diagnosed in most cases. Other side effects include vomiting, diarrhea, colitis, and skin rash but with low severity grades. For the LEAM arm, one patient died after transplant, before engrafting, one patient didn't achieve platelet engraftment in day 100, one patient developed grade 3 upper gastrointestinal bleeding, one patient died (grade 5 toxicity) with acute renal failure, one patient developed hypoxic events up to grade 4 acute respiratory failure and one patient developed grade 3 itchy skin rash. For the CLV arm, one patient died after transplant, before engrafting, one patient developed grade 3 colitis, one patient with grade 3 hepatic cytolysis, one patient with cardiac toxicity followed by death (grade 5) caused by an acute myocardial infarction with ST elevation and one patient with pulmonary toxicity clinically manifested with grade 3 pleurisy. For the BEAM arm, one patient developed grade 3 cardiac toxicity with sinus bradycardia and afterwards grade 4 with acute pulmonary edema, three patients presented a grade 3 pruritic skin rash and two patients developed grade 3 seizures. In the present study we presented the differences that were observed between BEAM, LEAM, and CLV conditioning regimens offering clinical arguments for an SCT practitioner choice in the ideal situation, but also of choice for alternative regimens in the case that one regimen cannot be used.
Collapse
Affiliation(s)
- Andrei Colita
- Department of Hematology, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.,Department of Stem Cell Transplantation, Coltea Clinical Hospital, Bucharest, Romania
| | - Anca Colita
- Department of Pediatrics, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.,Department of Stem Cell Transplantation, Fundeni Clinical Institute, Bucharest, Romania
| | - Horia Bumbea
- Department of Hematology, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.,Department of Stem Cell Transplantation, University Hospital, Bucharest, Romania
| | - Adina Croitoru
- Department of Stem Cell Transplantation, Fundeni Clinical Institute, Bucharest, Romania
| | - Carmen Orban
- Department of Stem Cell Transplantation, Fundeni Clinical Institute, Bucharest, Romania
| | - Lavinia Eugenia Lipan
- Department of Stem Cell Transplantation, Fundeni Clinical Institute, Bucharest, Romania
| | - Oana-Gabriela Craciun
- Department of Stem Cell Transplantation, Fundeni Clinical Institute, Bucharest, Romania
| | - Dan Soare
- Department of Hematology, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.,Department of Stem Cell Transplantation, University Hospital, Bucharest, Romania
| | - Cecilia Ghimici
- Department of Hematology, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.,Department of Stem Cell Transplantation, Coltea Clinical Hospital, Bucharest, Romania
| | - Raluca Manolache
- Department of Hematology, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.,Department of Stem Cell Transplantation, Coltea Clinical Hospital, Bucharest, Romania
| | - Ionel Gelatu
- Department of Hematology, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.,Department of Stem Cell Transplantation, Coltea Clinical Hospital, Bucharest, Romania
| | - Ana-Maria Vladareanu
- Department of Hematology, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
| | - Sergiu Pasca
- Department of Hematology, Research Center for Functional Genomics and Translational Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania.,Department of Hematology, Ion Chiricuta Clinical Cancer Center, Cluj Napoca, Romania
| | - Patric Teodorescu
- Department of Hematology, Ion Chiricuta Clinical Cancer Center, Cluj Napoca, Romania.,Department of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania
| | - Delia Dima
- Department of Hematology, Ion Chiricuta Clinical Cancer Center, Cluj Napoca, Romania
| | - Anca Lupu
- Department of Hematology, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.,Department of Stem Cell Transplantation, Coltea Clinical Hospital, Bucharest, Romania
| | - Daniel Coriu
- Department of Hematology, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.,Department of Hematology, Fundeni Clinical Institute, Bucharest, Romania
| | - Ciprian Tomuleasa
- Department of Hematology, Research Center for Functional Genomics and Translational Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania.,Department of Hematology, Ion Chiricuta Clinical Cancer Center, Cluj Napoca, Romania
| | - Alina Tanase
- Department of Stem Cell Transplantation, Fundeni Clinical Institute, Bucharest, Romania
| |
Collapse
|
27
|
Croitoru A, Dinu I, Herlea V, Becheanu G, Grasu M, Lupescu I, Dima SO, Buica F, Dumitrascu T, Lungulescu C, Croitoru VM, Tanase A, Negru SM, Gramaticu IM. LARGE CELL METASTATIC PANCREATIC NEUROENDOCRINE CARCINOMA TREATED WITH SOMATOSTATIN ANALOGUES - CASE REPORT AND LITERATURE REVIEW. Acta Endocrinol (Buchar) 2019; 15:390-397. [PMID: 32010361 DOI: 10.4183/aeb.2019.390] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
We report the case of a 55-year-old-male with a large cell metastatic pancreatic neuroendocrine carcinoma treated for 14 months with lanreotide autogel having a stable disease (SD) and not responding to chemotherapy. The somatostatin analogues (SSA) were introduced after an episode of diarrhea and controlled the disease. Progression-free survival (PFS) as determined by Computerized Tomography (CT) scans was obtained for 14 months. After more than a year, the patient's health state deteriorated along with progressive disease. The capecitabine-temozolomide regimen was challenged, but after three cycles, a rapid clinical decline was noted. Conclusion This unexpected event (diarrhea) in the course of the disease could represent the beginning of carcinoid syndrome. While the lanreotide autogel helped the episode of diarrhea pass, it also helped gain control over the disease itself.
Collapse
Affiliation(s)
- A Croitoru
- Fundeni Clinical Institute - Department of Medical Oncology, Bucharest, Romania.,"Titu Maiorescu" University, Faculty of Medicine, Bucharest, Romania
| | - I Dinu
- Fundeni Clinical Institute - Department of Medical Oncology, Bucharest, Romania
| | - V Herlea
- Fundeni Clinical Institute - Department of Pathology, Bucharest, Romania
| | - G Becheanu
- Fundeni Clinical Institute - Department of Pathology, Bucharest, Romania
| | - M Grasu
- Fundeni Clinical Institute - Department of Radiology and Medical Imaging, Bucharest, Romania
| | - I Lupescu
- Fundeni Clinical Institute - Department of Radiology and Medical Imaging, Bucharest, Romania
| | - S O Dima
- Fundeni Clinical Institute - Center of General Surgery and Liver Transplantation, Bucharest, Romania.,Fundeni Clinical Institute - Center of Excellence in Translational Medicine, Bucharest, Romania
| | - F Buica
- Fundeni Clinical Institute - Department of Medical Oncology, Bucharest, Romania.,"Titu Maiorescu" University, Faculty of Medicine, Bucharest, Romania
| | - T Dumitrascu
- Fundeni Clinical Institute - Center of General Surgery and Liver Transplantation, Bucharest, Romania
| | - C Lungulescu
- Dolj County Emergency Hospital - Department of Oncology, Craiova, Romania
| | - V M Croitoru
- Fundeni Clinical Institute - Department of Medical Oncology, Bucharest, Romania
| | - A Tanase
- Fundeni Clinical Institute - Bone Marrow Transplant Center, Bucharest, Romania.,"Titu Maiorescu" University, Faculty of Medicine, Bucharest, Romania
| | - S M Negru
- "Victor Babes" University of Medicine and Pharmacy, Timisoara, Romania
| | - I M Gramaticu
- Fundeni Clinical Institute - Department of Medical Oncology, Bucharest, Romania
| |
Collapse
|
28
|
Smira G, Croitoru A, Visan A, Luca I, Gramaticu I, Buica F, Dinu I, Brasoveanu V, Hrehoret D, Popescu I. Nexavar in treatment of hepatocellular carcinoma. Ro J Med Pract 2018. [DOI: 10.37897/rjmp.2018.4.7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
|
29
|
Cerban R, Ester C, Iacob S, Grasu M, Pâslaru L, Dumitru R, Lupescu I, Constantin G, Croitoru A, Gheorghe L. Predictive Factors of Tumor Recurrence and Survival in Patients with Hepatocellular Carcinoma treated with Transarterial Chemoembolization. J Gastrointestin Liver Dis 2018; 27:409-417. [PMID: 30574623 DOI: 10.15403/jgld.2014.1121.274.fcr] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/01/2022]
Abstract
BACKGROUND AND AIMS To evaluate the predictive factors for recurrence of the disease and overall survival (OS) after achieving complete response (CR) in patients with hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE). METHODS From January 2013 to December 2017, 168 treatment-naïve patients diagnosed with HCC underwent TACE as a first-line therapy and the gathered data was retrospectively reviewed. We determined the predictive factors for complete response (CR), for recurrence after CR and for survival using the Cox proportional hazard model. RESULTS Median follow-up was 27.4 months (range 4-65 months). The mean patient age was 62.2+/-7.9 years. Eighty-three patients had an α-fetoprotein (AFP) level > 20ng/mL. The median maximal diameter of the tumors was 3.5 cm. Sixty-three patients (37.5%) achieved CR after TACE, and recurrence after CR was detected in 37 patients (58.7%). In multivariate analysis, tumor size (</=4.5 cm) and a single tumor were found to be predictive factors for CR, with hazard ratios (HRs) of 2.352 (p=0.022) and 3.964 (p<0.0001), respectively. After achieving CR the median time to recurrence was 12 months (range 6-24 months). Elevated serum AFP > 25 ng/mL and multiple tumors were demonstrated to have a significant relationship with recurrence after CR, with HRs of 1.650 (p=0.05) and 3.932 (p=0.038), respectively. Increased initial serum AFP > 22 ng/mL, tumor size > 4.5 cm, outside Milan criteria, not receiving a liver transplant and presence of portal vein thrombosis (PVT) were correlated with poor survival. CONCLUSIONS In patients treated with TACE as an initial therapy, tumor size (≤4.5 cm) and single tumor were predictive factors for CR. Multiple nodules and an elevated serum AFP > 25 ng/mL were predictive factors for recurrence after CR. Outside Milan criteria tumors, elevated AFP levels and the presence of PVT were significantly correlated with decreased survival.
Collapse
Affiliation(s)
- Razvan Cerban
- Center for Digestive Diseases and Liver Transplantation, Fundeni Clinical Institute; Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
| | - Carmen Ester
- Center for Digestive Diseases and Liver Transplantation, Fundeni Clinical Institute; Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
| | - Speranta Iacob
- Center for Digestive Diseases and Liver Transplantation, Fundeni Clinical Institute; Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
| | - Mugur Grasu
- Center for Interventional Radiology and Medical Imaging, Fundeni Clinical Institute; Carol Davila University of Medicine and Pharmacy, Bucharest,Romania.
| | - Liliana Pâslaru
- Department of Biochemistry, Fundeni Clinical Institute, Bucharest,Romania
| | - Radu Dumitru
- Center for Interventional Radiology and Medical Imaging, Fundeni Clinical Institute; Carol Davila University of Medicine and Pharmacy, Bucharest,Romania
| | - Ioana Lupescu
- Center for Interventional Radiology and Medical Imaging, Fundeni Clinical Institute; Carol Davila University of Medicine and Pharmacy, Bucharest,Romania
| | | | - Adina Croitoru
- Department of Medical Oncology, Fundeni Clinical Institute, Bucharest, Romania
| | - Liana Gheorghe
- Center for Digestive Diseases and Liver Transplantation, Fundeni Clinical Institute; Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
| |
Collapse
|
30
|
Dima SO, Dumitrascu T, Pechianu C, Grigorie RT, Brasoveanu V, Sorop A, Lupescu I, Purnichescu-Purtan R, Croitoru A, Bacalbasa N, Tanase A, Tomescu DR, Herlea V, Popescu I. PROGNOSTIC FACTORS IN PATIENTS WITH SURGICAL RESECTION OF PANCREATIC NEUROENDOCRINE TUMOURS. Acta Endocrinol (Buchar) 2018; 14:389-393. [PMID: 31149288 PMCID: PMC6525773 DOI: 10.4183/aeb.2018.389] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
CONTEXT Pancreatic neuroendocrine tumours (PanNETs) are rare pancreatic neoplasms. PanNETs can be treated by multimodal approach including surgery, locoregional and systemic therapy. OBJECTIVE The aim of the present study is to evaluate predictive factors of overall survival in patients with PanNETs surgically treated at a single center. SUBJECTS AND METHODS The study group consisted of 120 patients with PanNETs who had undergone surgery at the Center of Digestive Diseases and Liver Transplantation of Fundeni Clinical Institute, Bucharest, Romania. Surgical resection of the primary tumor was performed in 110 patients. RESULTS Tumor size > 2 cm (p=0.048) (90% CI) lymph node involvement (p=0.048), ENET grade (p<0.001), distant metastases (p<0.001), Ki 67 index (<2%, 2-5%, 5-10%, 10-20%, >20%) (p<0.001) were identified as significant prognostic factors for OS on univariate analysis. Using multivariate Cox proportional regression model we found that distant metastases and Ki 67 index were independent risk factors for the survival outcome. CONCLUSIONS Surgery with curative intent should be considered in all cases if clinically appropriate and technically feasible. High grade (Ki67 index ≥10%) tumours were associated with a 2- fold increase in risk of death as compared to those with a Ki67 <10%.
Collapse
Affiliation(s)
- S O Dima
- Fundeni Clinical Institute - Center of Digestive Diseases and Liver Transplantation - Bucharest, Romania
- Fundeni Clinical Institute - Center of Excellence in Translational Medicine - Bucharest, Romania
| | - T Dumitrascu
- Fundeni Clinical Institute - Center of Digestive Diseases and Liver Transplantation - Bucharest, Romania
| | - C Pechianu
- Fundeni Clinical Institute - Center of Excellence in Translational Medicine - Bucharest, Romania
- Fundeni Clinical Institute - Department of Pathology - Bucharest, Romania
| | - R T Grigorie
- Fundeni Clinical Institute - Center of Digestive Diseases and Liver Transplantation - Bucharest, Romania
| | - V Brasoveanu
- Fundeni Clinical Institute - Center of Digestive Diseases and Liver Transplantation - Bucharest, Romania
| | - A Sorop
- Fundeni Clinical Institute - Center of Excellence in Translational Medicine - Bucharest, Romania
| | - I Lupescu
- Fundeni Clinical Institute - Department of Radiology and Medical Imaging - Bucharest, Romania
| | - R Purnichescu-Purtan
- Fundeni Clinical Institute - University Politehnica of Bucharest, Departament of Mathematical Methods and Models, Bucharest, Romania
| | - A Croitoru
- Fundeni Clinical Institute - Center of Digestive Diseases and Liver Transplantation - Bucharest, Romania
- Fundeni Clinical Institute - "Titu Maiorescu" University - "Acad. Nicolae Cajal" Institute of Medical Scientific Research, Bucharest, Romania
| | - N Bacalbasa
- Fundeni Clinical Institute - Center of Digestive Diseases and Liver Transplantation - Bucharest, Romania
- Fundeni Clinical Institute - Center of Excellence in Translational Medicine - Bucharest, Romania
| | - A Tanase
- Fundeni Clinical Institute - "Titu Maiorescu" University - "Acad. Nicolae Cajal" Institute of Medical Scientific Research, Bucharest, Romania
| | - D R Tomescu
- Fundeni Clinical Institute - Center of Digestive Diseases and Liver Transplantation - Bucharest, Romania
| | - V Herlea
- Fundeni Clinical Institute - Department of Pathology - Bucharest, Romania
- Fundeni Clinical Institute - "Titu Maiorescu" University - "Acad. Nicolae Cajal" Institute of Medical Scientific Research, Bucharest, Romania
| | - I Popescu
- Fundeni Clinical Institute - Center of Digestive Diseases and Liver Transplantation - Bucharest, Romania
- Fundeni Clinical Institute - "Titu Maiorescu" University - "Acad. Nicolae Cajal" Institute of Medical Scientific Research, Bucharest, Romania
| |
Collapse
|
31
|
Alexandrescu S, Diaconescu A, Ionel Z, Zlate C, Grigorie R, Hrehoreţ D, Braşoveanu V, Dima S, Botea F, Ionescu M, Tomescu D, Droc G, Fota R, Croitoru A, Gramaticu I, Buica F, Iacob R, Gheorghe C, Herlea V, Grasu M, Dumitru R, Boroş M, Popescu I. Comparative Analysis between Simultaneous Resection and Staged Resection for Synchronous Colorectal Liver Metastases - A Single Center Experience on 300 Consecutive Patients. Chirurgia (Bucur) 2017; 112:278-288. [PMID: 28675363 DOI: 10.21614/chirurgia.112.3.278] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/01/2017] [Indexed: 11/23/2022]
Abstract
Introduction: In synchronous colorectal liver metastases (SCLMs), simultaneous resection (SR) of the primary tumor and liver metastases has not gained wide acceptance. Most authors prefer staged resections (SgR), especially in patients presenting rectal cancer or requiring major hepatectomy. Methods: Morbidity, mortality, survival rates and length of hospital stay were compared between the two groups of patients (SR vs. SgR). A subgroup analysis was performed for patients with similar characteristics (e.g. rectal tumor, major hepatectomy, bilobar metastases, metastatic lymph nodes, preoperative chemotherapy). Results: Between 1995 and 2016, SR was performed in 234 patients, while 66 patients underwent SgR. Comparative morbidity (41% vs. 31.8%, respectively, p = 0.1997), mortality (3.8% vs. 3%, respectively, p = 1) and overall survival rates (85.8%, 51.3% and 30% vs. 87%, 49.6% and 22.5%, at 1-, 3- and 5-years, respectively, p = 0.386) were similar between the SR and SgR group. Mean hospital stay was significantly shorter in patients undergoing SR than SgR (15.11 +- 8.60 vs. 19.42 +- 7.36 days, respectively, p 0.0001). The characteristics of SR and SgR groups were similar, except the following parameters: rectal tumor (34.1% vs. 19.7%, respectively, p = 0.0245), metastatic lymph nodes (68.1% vs. 86.3%, respectively, p = 0.0383), bilobar liver metastases (22.6% vs. 37.8%, respectively, p = 0.0169), major hepatectomies (13.2% vs. 30.3%, respectively, p= 0.0025) and neo-adjuvant chemotherapy (13.2% vs. 77.2%, respectively, p 0.0001). A comparative analysis of morbidity, mortality and survival rates between SR and SgR was performed for subgroups of patients presenting these parameters. In each of these subgroups, SR was associated with similar morbidity, mortality and survival rates compared with SgR (p value 0.05). CONCLUSION In patients with SCLMs, SR provides similar short-term and long-term outcomes as SgR, with a shorter hospital stay. Therefore, in most patients with SCLMs, SR might be considered the treatment of choice.
Collapse
|
32
|
Diaconescu A, Alexandrescu S, Ionel Z, Zlate C, Grigorie R, Brasoveanu V, Hrehoret D, Ciurea S, Botea F, Tomescu D, Droc G, Croitoru A, Herlea V, Boros M, Grasu M, Dumitru R, Toma M, Ionescu M, Vasilescu C, Popescu I. Resection of Concomitant Hepatic and Extrahepatic Metastases from Colorectal Cancer - A Worthwhile Operation? Chirurgia (Bucur) 2017; 112:673-682. [DOI: 10.21614/chirurgia.112.6.673] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/01/2017] [Indexed: 11/23/2022]
|
33
|
Botea F, Ionescu M, Braşoveanu V, Hrehoreţ D, Alexandrescu S, Grigorie M, Stanciulea O, Nicolaescu D, Tomescu D, Droc G, Ungureanu D, Fota R, Croitoru A, Gheorghe L, Gheorghe C, Lupescu I, Grasu M, Boroş M, Dumitru R, Toma M, Herlea V, Popescu I. Liver Resections in a High-Volume Center: Form Standard Procedures to Extreme Surgery and Ultrasound-guided Resections. Chirurgia (Bucur) 2017; 112:259-277. [DOI: 10.21614/chirurgia.112.3.259] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/01/2017] [Indexed: 12/21/2022]
|
34
|
Grigorie R, Alexandrescu S, Smira G, Ionescu M, Hrehoreţ D, Braşoveanu V, Dima S, Ciurea S, Boeţi P, Dudus I, Picu N, Zamfir R, David L, Botea F, Gheorghe L, Tomescu D, Lupescu I, Boroş M, Grasu M, Dumitru R, Toma M, Croitoru A, Herlea V, Pechianu C, Năstase A, Popescu I. Curative Intent Treatment of Hepatocellular Carcinoma - 844 Cases Treated in a General Surgery and Liver Transplantation Center. Chirurgia (Bucur) 2017; 112:289-300. [DOI: 10.21614/chirurgia.112.3.289] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/01/2017] [Indexed: 11/23/2022]
|
35
|
Duchenne J, Popara-Voica AM, Duchenne J, Aruta P, Teo HK, Onciul S, Miskowiec D, Onciul S, Rumbinaite E, Abellard JA, Turco A, Claus P, Vunckx K, Pagourelias E, Rega F, Gheysens O, Voigt JU, Croitoru A, Alexandru D, Geavlete DO, Popescu BA, Ginghina C, Jurcut R, Claus P, Turco A, Vunckx K, Pagourelias E, Haemers P, Van Puyvelde J, Gheysens O, Rega F, Voigt JU, Muraru D, Janei C, Haertel Miglioranza M, Cavalli G, Romeo G, Peluso D, Cucchini U, Iliceto S, Badano L, Kui SL, Chai SC, Leong KT, Tong KL, Muraru D, Miglioranza MH, Cucchini U, Dorobantu M, Iliceto S, Badano LP, Kupczynska K, Uznanska-Loch B, Kasprzak JD, Kurpesa M, Lipiec P, Muraru D, Miglioranza MH, Cucchini U, Dorobantu M, Iliceto S, Badano LP, Vaskelyte JJ, Lapinskas T, Karuzas A, Zvirblyte R, Viezelis M, Jonauskiene I, Gustiene O, Slapikas R, Trochu JN, Gueffet JP, Cueff C, De Groote P, Bauters C, Millaire A, Polge AS, Le Tourneau T. HIT Moderated Poster session: imaging in everyday practiceP143Relationship of FDG-PET and pressure-strain loops as novel measures of regional myocardial workload in LBBB-like dyssynchronyP144Cardiotoxicity of anti-vascular endothelial growth factor therapies: results of a pilot studyP145A new animal model of rapid pacing-induced dilated cardiomyopathy and LBBBP146Three-dimensional echocardiography assessment of the systolic variation of effective regurgitant orifice area in patients with functional tricuspid regurgitation: implications for quantificationP147Clinical prognostic value of myocardial mechanics using speckle-tracking echocardiography in patients post primary coronary intervention for acute ST- segment elevation myocardial infarctionP148Relationship between left atrial volumes and emptying fractions and parameters of infarct size and left ventricular filling pressures in survivors of st elevation myocardial infarctionP149Left atrial dysfunction assessed by two dimensional speckle tracking echocardiography in patients with impaired left ventricular ejection fraction and sleep-disordered breathingP150Left atrial morphological and functional remodeling early after ST elevation myocardial infarction insights from threedimensional echocardiographyP151Circumferential strain and strain rate at early stages of dobutamine speckle tracking imaging: are they enough to detect ischemia in patients with coronary artery disease?P152Pulmonary hypertension in hypertrophic cardiomyopathy: a rest and exercise echocardiography study. Eur Heart J Cardiovasc Imaging 2015. [DOI: 10.1093/ehjci/jev261] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
36
|
Daniele B, Croitoru A, Papandreou C, Bronowicki JP, Mathurin P, Serejo F, Stål P, Turnes J, Ratziu V, Bodoky G. Impact of sorafenib dosing on outcome from the European patient subset of the GIDEON study. Future Oncol 2015; 11:2553-62. [DOI: 10.2217/fon.15.163] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
SUMMARY Aims: To evaluate sorafenib dosing and safety in the Global Investigation of therapeutic GIDEON study's European subpopulation. Patients & methods: Patient demographics, disease characteristics and treatment history were recorded at enrollment; dose, adverse events and efficacy were recorded at follow-up. Results: Of 1113 evaluable patients, 82% started on 800 mg/day sorafenib; patients starting on 400 mg/day were slightly older, had baseline characteristics indicative of greater disease progression and higher adverse events incidences (96 vs 88%). Treatment duration (18.0 vs 13.0 weeks) and median overall survival (12.1 vs 9.4 months) were longer in patients receiving 800 mg/day. Conclusion: Imbalances in independent predictive factors may have led to longer survival in patients receiving 800 mg/day sorafenib; nonetheless, results suggest that the majority can start on this dose.
Collapse
Affiliation(s)
- Bruno Daniele
- Department of Oncology, G Rummo Hospital, Benevento, Italy
| | - Adina Croitoru
- Department of Medical Oncology, Fundeni Clinical Institute, Bucharest, Romania
| | - Christos Papandreou
- Department of Medical Oncology, University Hospital of Larissa, Larissa, Greece
| | - Jean-Pierre Bronowicki
- Department of Hepatogastroenterology, Centre Hospitalier Universitaire de Nancy, Université Henri Poincaré–Nancy, Vandoeuvre-lès-Nancy, France
| | - Philippe Mathurin
- Services des Maladies de l'Appareil Digestif, Hôpital Claude Huriez, Lille, France
| | - Fatima Serejo
- Center of Gastroenterology, Liver Unit, Hospital de Santa Maria, Faculty of Medicine, Lisbon, Portugal
| | - Per Stål
- Department of Gastroenterology & Hepatology, Karolinska University Hospital, Huddinge, Stockholm, Sweden
| | - Juan Turnes
- Gastroenterology Department, Hospital de Montecelo, Complejo Hospitalario de Pontevedra, Pontevedra, Spain
| | - Vlad Ratziu
- Service d'Hépato-Gastroentérologie, Université Pierre et Marie Curie and Hospital Pitié Salpêtrière, Paris, France
| | - György Bodoky
- Department of Oncology, St László Teaching Hospital, Budapest, Hungary
| |
Collapse
|
37
|
Chirita D, Calita M, Grasu M, Dumitru R, Gramaticu I, Croitoru A, Ionescu M, Dumitrascu T. Metachronous Ampulla of Vater Carcinoma after Curative-Intent Surgery for Klatskin Tumor. Chirurgia (Bucur) 2015; 110:379-383. [PMID: 26305204] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/01/2015] [Indexed: 06/04/2023]
Abstract
Resection represents the single hope for long-term survival in a patient diagnosed with a hilar cholangiocarcinoma (Klatskin tumor). However, the largest part of these patients develops a recurrent disease. Second metachronous periampullary cancers after a curative-intent surgery for a Klatskin tumor represent an exceptional pathology, and the management of these patients was poorly documented. Hereby, it is presented a 32-year-old patient with bile duct resection, left hemi-hepatectomy and loco-regional lymph nodes dissection, for a type IIIB Bismuth-Corlette Klatskin tumor, which, furthermore, 6 years later, underwent a pancreaticoduodenectomy for a metachronous carcinoma of the ampulla of Vater. The management and outcomes were discussed in the reported case, along with a literature review of the previously published patients. In conclusion, a metachronous periampullary carcinoma after resection of a Klatskin tumor should be distinguished from a loco-regional recurrent disease. While most of the patients with recurrences are suitable to only chemotherapy and or radiotherapy, a second curative-intent surgery (i.e., pancreaticoduodenectomy) is feasible in the largest part of the patients with a metachronous cancer, with good long-term outcomes.
Collapse
|
38
|
Gafton B, Porumb V, Ungurianu S, Marinca MV, Cocea C, Croitoru A, Balan G, Miron N, Eliade Ciuleanu T, Miron L. Hepatocellular carcinoma: insights in the biological treatment beyond sorafenib. J BUON 2014; 19:858-866. [PMID: 25536587] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
UNLABELLED Hepatocellular carcinoma has an increasing incidence and an impressive mortality. At present, the only authorized systemic treatment is the multi-kinase inhibitor sorafenib. A multitude of clinical trials are aimed at improving outcomes, both in firstY- and in second-line therapy. In this multitude of clinical trials, the purpose of our article was to familiarize physicians with the mechanisms of action of new biological therapies and to offer an algorithm for optimal trial selection for each patient, based on clinical and biological indicators. The available data were structured as follows: antiangiogenic therapy, c -MET inhibitors, combinations of chemotherapy with sorafenib, immune response modulators, cellular metabolism modulators, mTOR inhibitors, other multi-kinase inhibitors. CONCLUSION Treatment of advanced hepatocellular carcinoma remains a challenge for oncologists. Choosing the "right" trial may be the only chance of prolonging patient survival and improve his/her clinical status.
Collapse
Affiliation(s)
- Bogdan Gafton
- The University of Medicine and Pharmacy "Gr. T. Popa", Iasi, Romania
| | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Negru S, Papadopoulou E, Apessos A, Stanculeanu DL, Ciuleanu E, Volovat C, Croitoru A, Kakolyris S, Aravantinos G, Ziras N, Athanasiadis E, Touroutoglou N, Pavlidis N, Kalofonos HP, Nasioulas G. KRAS, NRAS and BRAF mutations in Greek and Romanian patients with colorectal cancer: a cohort study. BMJ Open 2014; 4:e004652. [PMID: 24859998 PMCID: PMC4039802 DOI: 10.1136/bmjopen-2013-004652] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
OBJECTIVES Treatment decision-making in colorectal cancer is often guided by tumour tissue molecular analysis. The aim of this study was the development and validation of a high-resolution melting (HRM) method for the detection of KRAS, NRAS and BRAF mutations in Greek and Romanian patients with colorectal cancer and determination of the frequency of these mutations in the respective populations. SETTING Diagnostic molecular laboratory located in Athens, Greece. PARTICIPANTS 2425 patients with colorectal cancer participated in the study. PRIMARY AND SECONDARY OUTCOME MEASURES 2071 patients with colorectal cancer (1699 of Greek and 372 of Romanian origin) were analysed for KRAS exon 2 mutations. In addition, 354 tumours from consecutive patients (196 Greek and 161 Romanian) were subjected to full KRAS (exons 2, 3 and 4), NRAS (exons 2, 3 and 4) and BRAF (exon 15) analysis. KRAS, NRAS and BRAF mutation detection was performed by a newly designed HRM analysis protocol, followed by Sanger sequencing. RESULTS KRAS exon 2 mutations (codons 12/13) were detected in 702 of the 1699 Greek patients with colorectal carcinoma analysed (41.3%) and in 39.2% (146/372) of the Romanian patients. Among the 354 patients who were subjected to full KRAS, NRAS and BRAF analysis, 40.96% had KRAS exon 2 mutations (codons 12/13). Among the KRAS exon 2 wild-type patients 15.31% harboured additional RAS mutations and 12.44% BRAF mutations. The newly designed HRM method used showed a higher sensitivity compared with the sequencing method. CONCLUSIONS The HRM method developed was shown to be a reliable method for KRAS, NRAS and BRAF mutation detection. Furthermore, no difference in the mutation frequency of KRAS, NRAS and BRAF was observed between Greek and Romanian patients with colorectal cancer.
Collapse
Affiliation(s)
- Serban Negru
- University of Medicine and Pharmacy of Timisoara, Timisoara, Romania
| | | | - Angela Apessos
- Department of Molecular Biology, GENEKOR, Athens, Greece
| | | | | | | | - Adina Croitoru
- Department of Medical Oncology, Fundeni Clinical Institute Bucharest, Bucharest, Romania
| | - Stylianos Kakolyris
- Department of Medical Oncology, University General Hospital of Alexandroupolis, Thrace, Greece
| | - Gerasimos Aravantinos
- Second Department of Medical Oncology, “Agii Anargiri” Cancer Hospital, Athens, Greece
| | - Nikolaos Ziras
- First Department of Medical Oncology, ‘METAXA’ Anticancer Hospital of Athens, Athens, Greece
| | | | | | - Nikolaos Pavlidis
- Department of Medical Oncology, University of Ioannina School of Medicine, Ioannina, Greece
| | - Haralabos P Kalofonos
- Clinical Oncology Laboratory, Division of Oncology, Department of Medicine, University of Patras, Patras Medical School, Rio, Greece
| | | |
Collapse
|
40
|
Iacob R, Iacob S, Gheorghe L, Gheorghe C, Hrehoreţ D, Brașoveanu V, Croitoru A, Herlea V, Popescu I. Outcome of liver transplantation for hepatocellular carcinoma -- a single center experience. Chirurgia (Bucur) 2013; 108:446-450. [PMID: 23958083] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/01/2013] [Indexed: 06/02/2023]
Abstract
BACKGROUND & AIMS Liver transplantation (LT) is a promising treatment for patients with liver cirrhosis associated with hepatocellular carcinoma (HCC). The aim of our study was to evaluate our experience regarding the clinical and pathological staging of HCC in patients who underwent LT, as well as recurrence free and overall survival. METHODS From January 2006 to December 2011, 38 patients with diagnosis of HCC, underwent LT in our Center. Demographic, clinical, imaging and pathologic information were recorded. A Cox proportional hazards survival analysis was performed in order to identify significant predictors of tumor recurrence and patient's death after LT. RESULTS Eighteen patients (47.4%) in our study group were within Milan criteria. The mean follow-up was 22 months and the recurrence rate of HCC after LT was 13.2%. The 1, 3- year recurrence free survival rates were 85%, 74.3% respectively. The 1 and 3-year overall survival rates were 83.5% and 63.6% respectively. No significant predictor for HCC recurrence was identified in our study group by survival analysis, taking into account 13 different variables. As independent predictors of patient'ss death after LT for HCC however, the presence of diabetes mellitus (p=0.001), presence of more than 3 HCC nodules (p=0.03) and tumor recurrence after LT (p=0.03) were identified by multivariate Cox proportional hazards survival analysis. CONCLUSION In our cohort HCC recurrence rate after LT was 13.2%. Diabetes mellitus, presence of more than 3 HCC nodules and HCC recurrence were significant predictors of poor overall survival after LT.
Collapse
Affiliation(s)
- R Iacob
- Fundeni Clinical Institute, Bucharest, Romania
| | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Pinter T, Abella E, Cesas A, Croitoru A, Decaestecker J, Gibbs P, Hotko Y, Jassem J, Kurteva GP, Novotny J, O'Reilly S, Salek T, Mo MF, Choi LMR, Blanke CD. Results of a phase III, randomized, double-blind, placebo-controlled trial of pegfilgrastim (PEG) in patients (pts) receiving first-line FOLFOX or FOLFIRI and bevacizumab (B) for colorectal cancer (CRC). J Clin Oncol 2013. [DOI: 10.1200/jco.2013.31.15_suppl.3575] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
3575 Background: The literature reports that adding biologics to chemotherapy (ctx) may increase the incidence of clinically significant neutropenia. his trial was conducted to evaluate the efficacy of PEG in reducing the incidence of febrile neutropenia (FN) in pts with locally-advanced (LA) or metastatic (m)CRC receiving first-line treatment with either FOLFOX/B or FOLFIRI/B. Methods: Key eligibility: ≥ 18 years old; measurable, nonresectable CRC per RECIST 1.1. Pts were randomly assigned 1:1 to either placebo or 6 mg PEG ~24 h after ctx/B. The study treatment period included four Q2W cycles, but pts could continue their assigned regimen until progression. Pts were stratified by region (North America vs rest of world), stage (LA vs mCRC), and ctx (FOLFOX vs FOLFIRI). Estimated sample size (N = 800) was based on the expected incidence of grade 3/4 FN (primary endpoint) across the first 4 cycles of ctx/B, powered for PEG superiority over placebo. Other endpoints included overall response rate (ORR), progression-free survival (PFS), and overall survival (OS). Results: 845 pts were randomized (Nov 2009 to Jan 2012) and received study treatment; 783 pts completed 4 cycles of ctx/B. Median age was 61 years; 512 (61%) pts were male; 819 (97%) had mCRC; 414 (49%) received FOLFOX, and 431 (51%) received FOLFIRI. Grade 3/4 FN (first 4 cycles) for placebo vs PEG was 5.7% vs 2.4%; OR 0.41; p = 0.014. A similar incidence of other ≥ grade 3 adverse events was seen in both arms (28% placebo; 27% PEG). See table for additional results. Conclusions: PEG significantly reduced the incidence of grade 3/4 FN in this pt population receiving standard ctx/B for CRC. Follow-up is ongoing. Clinical trial information: NCT00911170. [Table: see text]
Collapse
Affiliation(s)
| | | | | | - Adina Croitoru
- Fundeni Clinical Institute for Digestive Disorders, Bucharest, Romania
| | | | - Peter Gibbs
- Royal Melbourne Hospital, Parkville, Australia
| | | | | | | | - Jan Novotny
- Institute of Oncology and Rehabilitation, Na Plesi, Czech Republic
| | - Seamus O'Reilly
- Department of Medical Oncology, Cork University Hospital, Cork, Ireland
| | - Tomas Salek
- National Cancer Institute, Bratislava, Slovakia
| | | | | | - Charles Davic Blanke
- University of British Columbia/British Columbia Cancer Agency, Vancouver, BC, Canada
| |
Collapse
|
42
|
Pinter T, Abella S, Cesas A, Croitoru A, Decaestecker J, Gibbs P, Hotko Y, Jassem J, Kurteva GP, Novotny J, O'Reilly S, Salek T, Mo MF, Choi LMR, Blanke CD. Results of a phase III, randomized, double-blind, placebo-controlled trial of pegfilgrastim (PEG) in patients (pts) receiving first-line FOLFOX or FOLFIRI and bevacizumab (B) for colorectal cancer (CRC). J Clin Oncol 2013. [DOI: 10.1200/jco.2013.31.4_suppl.lba445] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
LBA445 Background: The literature reports that adding biologics to chemotherapy (ctx) may increase the incidence of clinically significant neutropenia. This trial was conducted to evaluate the efficacy of PEG in reducing the incidence of febrile neutropenia (FN) in pts with locally advanced (LA) or metastatic (m)CRC receiving first-line treatment with either FOLFOX/B or FOLFIRI/B. Methods: Key eligibility: ≥ 18 years old; measurable, nonresectable CRC per RECIST 1.1. Pts were randomly assigned 1:1 to either placebo or 6 mg PEG ~24 h after ctx/B. The study treatment period included four Q2W cycles, but pts could continue their assigned regimen until progression. Pts were stratified by region (North America vs rest of world), stage (LA vs mCRC), and ctx (FOLFOX vs FOLFIRI). Estimated sample size (N = 800) was based on the expected incidence of grade 3/4 FN (primary endpoint) across the first 4 cycles of ctx/B, powered for PEG superiority over placebo. Other endpoints included overall response rate (ORR), progression-free survival (PFS), and overall survival (OS). Results: 845 pts were randomized (Nov 2009 to Jan 2012) and received study treatment; 783 pts completed 4 cycles of ctx/B. Median age was 61 years; 512 (61%) pts were male; 819 (97%) had mCRC; 414 (49%) received FOLFOX, and 431 (51%) received FOLFIRI. Grade 3/4 FN (first 4 cycles) for placebo vs PEG was 5.7% vs 2.4%; OR 0.41; p = 0.014. A similar incidence of other ≥ grade 3 adverse events was seen in both arms (28% placebo; 27% PEG). See Table for additional results. Conclusions: PEG significantly reduced the incidence of grade 3/4 FN in this pt population receiving standard ctx/B for CRC. Follow-up is ongoing. Clinical trial information: NCT00911170. [Table: see text]
Collapse
Affiliation(s)
| | | | | | - Adina Croitoru
- Fundeni Clinical Institute for Digestive Disorders, Bucharest, Romania
| | | | | | | | | | | | - Jan Novotny
- Institute of Oncology and Rehabilitation, Na Plesi, Czech Republic
| | - Seamus O'Reilly
- Department of Medical Oncology, Cork University Hospital, Cork, Ireland
| | - Tomas Salek
- National Cancer Institute, Bratislava, Slovakia
| | | | | | - Charles Davic Blanke
- University of British Columbia/British Columbia Cancer Agency, Vancouver, BC, Canada
| |
Collapse
|
43
|
Poiana C, Carsote M, Trifanescu R, Terzea D, Croitoru A. Case study of appendiceal carcinoid during pregnancy. J Med Life 2012; 5:325-8. [PMID: 23049637 PMCID: PMC3465003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2012] [Accepted: 08/28/2012] [Indexed: 11/23/2022] Open
Abstract
The carcinoid tumor of the appendix is one of the most common tumors of the appendix, but one of the rarest anatomic locations of carcinoids. The prognosis is very good, as most tumors are incidentally discovered during surgery for acute or sub-acute appendicitis. The diagnosis is exceptional when combined with pregnancy. We present such a case of a 27-year-old female patient. An emergency appendectomy was performed, and soon after, pregnancy was confirmed. The patient had a tumor smaller than 1 cm in diameter, at the tip of the appendix. The immunochemistry revealed the neuroendocrine profile by positive reaction for chromogranin A and synaptophysin, with a ki-67 profile at an undetectable level. After surgery, the neuroendocrine markers and the octreoscan were negative, consequently indicating a favorable prognosis. Further follow-up is necessary, even though not all the authors recommend it (considering the low index to the associated metastases, especially for small appendiceal tumors).
A short review of the literature is presented, starting with this case report.
Collapse
Affiliation(s)
- C Poiana
- Endocrinology Department, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
| | | | | | | | | |
Collapse
|
44
|
Croitoru A, Gramaticu I, Dinu I, Gheorghe L, Alexandrescu S, Buica F, Luca I, Becheanu G, Herlea V, Simionov I, Hrehoret D, Lupescu I, Popescu I, Diculescu M. Fluoropyrimidines plus cisplatin versus gemcitabine/gemcitabine plus cisplatin in locally advanced and metastatic biliary tract carcinoma - a retrospective study. J Gastrointestin Liver Dis 2012; 21:277-284. [PMID: 23012669] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
AIM This is a retrospective study of patients with advanced biliary tract carcinoma (BTC), who were treated with different regimens of chemotherapy. METHODS We studied patients with advanced BTC registered at the Department of Oncology at the Fundeni Clinical Institute between 2004 and 2008. The following data were analyzed: rate of response, progression free survival (PFS) to first and second line of chemotherapy, overall survival (OS) and drug toxicity. Ninety-six patients were eligible having either advanced intra or extrahepatic cholangiocarcinoma, or gallbladder cancer with no prior chemotherapy. RESULTS Out of 96 patients, 57 (59.4%) received fluoropyrimidines (FP)+cisplatin and 39 (40.6%) gemcitabine (Gem)+/-cisplatin. The median PFS for FP+cisplatin was 5.9 months (95%CI 5-6.9) and for Gem+/-cisplatin 6.3 months (95%CI 5.4-7.1), p=0.661. Median OS for FP+cisplatin was 10.3 months (95%CI 7.5-13.1) and for Gem+/-cisplatin 9.1 months (95%CI 7.0-11.2), p=0.098. On disease progression, 46 patients received second line CT (Gem or FP+/-platinum compounds). Median OS for patients with FP based first line and Gem+/-cisplatin in second line was 19 months (95%CI 8.9-29) higher than for the reverse sequence: 13.2 months (95%CI 12-14.4), but not statistically significant (p=0.830). All patients were evaluated for toxicities. Most patients (75.5%) reported at least one adverse event. CONCLUSION Our results through direct comparison of FP+cisplatin with Gem+/-cisplatin as first line treatment did not show any statistical differences in terms of rate of response, PFS and OS. However, our study showed that FP+cisplatin as first line and Gem based second line therapy gave a better OS rate.
Collapse
Affiliation(s)
- Adina Croitoru
- Department of Medical Oncology, Fundeni Clinical Institute Bucharest, Romania.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Daniele B, Turnes J, Bodoky G, Papandreou C, Hubert A, Stål P, Gorbunova V, Serejo F, Croitoru A, Mathurin P. Second Interim Analysis of the Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of its Treatment with Sorafenib (GIDEON) Study According to Disease Stage. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)33247-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
46
|
Alexandrescu S, Hrehoreţ D, Ionel Z, Croitoru A, Anghel R, Popescu I. Simultaneous resection of the primary colorectal tumor and liver metastases--a safe and effective operation. Chirurgia (Bucur) 2012; 107:298-307. [PMID: 22844827] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
BACKGROUND The aim of this retrospective study was to compare the results achieved by simultaneous resection (SR) vs. delayed resection (DR) in patients with synchronous colorectal liver metastases (SCRLM). METHODS In "Dan Setlacec" Center of General Surgery and Liver Transplantation from Fundeni Clinical Institute, between 1995 and 2010, 117 patients underwent SR and 25 patients underwent DR. It was compared the outcome of the patients in the two groups. It was also assessed if certain subgroups of patients present a better outcome after DR than after SR. RESULTS The location of the primary tumor, the number and diameter of liver metastases, and the proportion of major hepatectomies were similar in the two groups (p value > 0.05). For all patients, the morbidity, mortality, disease-free and overall surrvival rates were not statistically significant different between the two groups (p value > 0.05). In subgroups of patients with rectal tumors, with multiple liver metastases, and undergoing major hepatectomies, the morbidity, mortality and survival rates achieved by SR were similar to those achieved by DR. CONCLUSION Simultaneous resection of SCRLM is similarly safe and efficient as the delayed resection, even in patients with rectal tumors, with multiple liver metastases, or undergoing major hepatectomies.
Collapse
Affiliation(s)
- S Alexandrescu
- Dan Setlacec Center of General Surgery and Liver Transplantation, Fundeni Clinical Institute, Bucharest, Romania
| | | | | | | | | | | |
Collapse
|
47
|
Vrdoljak E, Wojtukiewicz MZ, Pienkowski T, Bodoky G, Berzinec P, Finek J, Todorović V, Borojević N, Croitoru A. Cancer epidemiology in Central, South and Eastern European countries. Croat Med J 2012; 52:478-87. [PMID: 21853542 PMCID: PMC3160694 DOI: 10.3325/cmj.2011.52.478] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Abstract
AIM To collect cancer epidemiology data in South Eastern European countries as a basis for potential comparison of their performance in cancer care. METHODS The South Eastern European Research Oncology Group (SEEROG) collected and analyzed epidemiological data on incidence and mortality that reflect cancer management in 8 countries - Croatia, Czech Republic, Hungary, Romania, Poland, Slovakia, and Serbia and Montenegro in the last 20-40 years. RESULTS The most common cancer type in men in all countries was lung cancer, followed by colorectal and prostate cancer, with the exception of the Czech Republic, where prostate cancer and colorectal cancer were more common. The most frequent cancer in women was breast cancer followed by colorectal cancer, with the exceptions of Romania and Central Serbia where cervical cancer was the second most common. Cancer mortality data from the last 20-40 years revealed two different patterns in men. In Romania and in Serbia and Montenegro, there was a trend toward an increase, while in the other countries mortality was declining, after increasing for a number of years. In women, a steady decline was observed over many years in the Czech Republic, Hungary, and Slovakia, while in the other countries it remained unchanged. CONCLUSIONS There are striking variations in the risk of different cancers by geographic area. Most of the international variation is due to exposure to known or suspected risk factors which provides a clear challenge to prevention. There are some differences in incidence and mortality that cannot be explained by exposure to known risk factors or treatment availabilities.
Collapse
Affiliation(s)
- Eduard Vrdoljak
- University Hospital Split, School of Medicine, Center of Oncology, Spincićeva 1, 21000 Split, Croatia.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Pătraşcu F, Croitoru A, Gramaticu I, Andrei M, Teiuţanu A, Diculescu M. [Locally advanced or metastatic gastric cancer--new therapeutic solutions]. Rev Med Chir Soc Med Nat Iasi 2011; 115:20-26. [PMID: 21688555] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
Gastric cancer represents a major health problem worldwide. It is often diagnosed at an advanced stage, because screening, which would help an early detection is performed only in Japan. Gastric cancer rates may be decreased by reducing smoking and alcohol consumption and by increasing the number of fresh fruits and vegetables eaten. Eradication of Helicobacter pylori may also decrease gastric cancer incidence. Seventy-five percent of the patients are diagnosed in unresectable stage. They represent a challenge for clinicians as they have to choose between a strictly supportive approach or to expose patients to the side-effects of a potentially ineffective treatment. The treatment of advanced gastric cancer is essentially palliative. Therapy's main aim in this common group of patients with unresectable or metastatic disease is to achieve good symptomatic control, to improve quality of life, to avoid tumor progression and to prolong survival.
Collapse
Affiliation(s)
- Florina Pătraşcu
- Compartimentul de Oncologie Medicala, Institutul Clinic de Boli Digestive si Transplant Hepatic Fundeni (ICBDTHF)
| | | | | | | | | | | |
Collapse
|
49
|
Smira G, Gheorghe L, Gheorghe C, Becheanu G, Croitoru A. QUIZ HQ 57. Multicentric carcinomas of the gastrointestinal tract. J Gastrointestin Liver Dis 2010; 19:204-218. [PMID: 20593058] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/29/2023]
Affiliation(s)
- Gabriela Smira
- Center of Gastroenterology and Hepatology, Fundeni Clinical Institute of Digestive Diseases and Liver Transplantation, Bucharest, Romania
| | | | | | | | | |
Collapse
|
50
|
Dima SO, Iacob S, Botea F, Matei E, Dorobanfu B, Vasile S, Alexandrescu S, Croitoru A, Dumitrascu T, Stroescu C, Herlea V, Popescu I. Multimodal treatment of hepatocellular carcinoma: an eastern European experience. Hepatogastroenterology 2009; 56:1696-1703. [PMID: 20214220] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
BACKGROUND/AIMS The aim of the present study was to evaluate the outcomes of a multimodal treatment approach of hepatocellular carcinoma (HCC) in a tertiary hepatobiliary specialty center. METHODOLOGY A total of 294 consecutive patients treated for HCC were retrospectively analyzed. Two hundred sixteen patients (73.4%) were men and 78 (26.6%) were women. Liver resection (LR) was performed in 201 patients (68.4%), liver transplantation (LT) in 19 patients (6.5%), radiofrequency ablation (RFA) in 74 patients (25.1%), and 56 (19%) patients received adjuvant systemic chemotherapy. RESULTS The median follow-up was 15.7 mo (range 0.1-90.3). Five-year overall survival and recurrence rates were 28% and 26.8%, respectively. Serum AFP > 43.8ng/ml (p = 0.005), BCLC C/D (p = 0.006) and JIS 3/4/5 classifications (p = 0.02) were independent negative prognostic factors for overall survival, while JIS 3/4/5 (p = 0.01) and BCLC C/D (p = 0.01) classifications, tumors larger than 6.5cm (p = 0.001) and RFA (p = 0.02) were independent predictors for recurrence. CONCLUSIONS The current treatment of HCC should be multimodal, and therapeutic modalities and their combinations should be tailored to each patient. LT represents the best therapeutic option for patients with HCC in the setting of cirrhosis. Resection remains a good option in cirrhotic patients, while RFA is a safe and effective procedure for small tumors.
Collapse
Affiliation(s)
- Simona Olimpia Dima
- Center of General Surgery and Liver Transplantation, Fundeni Clinical Institute of Digestive Disease and Liver Transplantation, Bucharest, Romania
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|